Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
Patent Information
- Application Number
- JP2024087782
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2012-03-06
- Filing Date
- 2024-05-30
- Publication Date
- 2024-11-15
AI Technical Summary
There is a need to identify human-derived commensal bacterial species that can potently induce IL-10 production in regulatory T cells (Tregs) to enhance immunosuppression, which can be used to treat autoimmune diseases, inflammatory diseases, and other conditions, as current methods do not effectively utilize human microbiome symbionts that have not been cultured.
The development of bacterial compositions comprising human-derived Clostridium species and their culture supernatants, or physiologically active substances derived from them, which induce the proliferation and accumulation of regulatory T cells, particularly in the large intestine, thereby enhancing immunosuppression.
These bacterial compositions effectively induce regulatory T cells to suppress immune responses, providing a natural and long-lasting therapeutic option for autoimmune diseases, inflammatory diseases, and immune-mediated conditions, offering a patient-friendly alternative to synthetic drugs.
Smart Images

Figure 00000068_0000 
Figure 00000069_0000 
Figure 00000104_0000
Abstract
Description
[Technical field]
[0001] The subject matter of the invention described herein relates to a human-derived bacterial composition that induces proliferation, accumulation, or proliferation and accumulation of regulatory T cells, and contains as active ingredients (a) one or more (one, at least one) types of human-derived bacteria belonging to the genus Clostridium, (b) one or more (one, at least one) types of culture supernatant of said bacteria, (c) one or more physiologically active substances derived from said bacteria, or (d) a combination of any two or more of the above. The subject matter of the invention described herein also relates to a method for inducing proliferation, accumulation, or proliferation and accumulation of regulatory T cells. A composition containing any of the above (a) to (d) is referred to as a bacterial composition. Furthermore, the subject matter of the present invention relates to a method for treating or preventing at least one disease or condition responsive to regulatory T cell induction, such as an autoimmune disease, an inflammatory disease, and an infectious disease, by administering the bacterial composition to an individual in need thereof. [Background technology]
[0002] Hundreds of species of commensal microbes colonize the mammalian digestive tract and interact with the host immune system. Studies using germ-free (GF) animals have shown that commensal microbes affect the development of the mucosal immune system, including the organization of Peyer's patches (PPs) and isolated lymphoid follicles (ILFs), the secretion of antimicrobial peptides from the epithelium, and the accumulation of intrinsic lymphocytes in mucosal tissues, including immunoglobulin A-producing plasma cells, intraepithelial lymphocytes, IL-17-producing CD4+ T cells (Th17), and IL-22-producing NK-like cells (NPLs 1-7). As a result, the presence of enteric bacteria enhances mucosal defenses, enabling the host to mount a strong immune response against pathogenic microbes that invade the body. Meanwhile, the mucosal immune system remains unresponsive to food antigens and harmless microbes (NPL 3). Dysregulation of the crosstalk between commensal bacteria and the immune system (gut dysbiosis) can lead to an overly strong immune response to environmental antigens, resulting in inflammatory bowel disease (IBD) (NPL8-10).
[0003] Recent research findings have revealed that individual commensal bacteria control the differentiation of specific immune cells in the mucosal immune system. For example, the human commensal bacterium Bacteroides fragilis specifically induces systemic Th1 cell responses and mucosal IL-10-producing T cell responses in mice, playing a role in protecting the host from pathogen-induced colitis (NPL3). Segmented filamentous bacteria, which are commensal bacteria in the mouse gut, induce mucosal Th17 cell responses and enhance the host's resistance to gastrointestinal pathogen infection (NPL11-13). In addition, it is known that short-chain fatty acids derived from some commensal bacteria suppress intestinal inflammation (NPL14). It has also been observed that the presence of some species of gut microbiota has a profound effect on the differentiation of regulatory T cells (hereafter referred to as "Treg cells"), which help maintain homeostasis of the immune system. Although specific species of mouse commensal bacteria that can potently stimulate Tregs have been identified (NPL15), it remains to be determined whether human commensal bacterial species have a comparable effect on the human immune system. Furthermore, the human intestinal tract is home to over 1,000 bacterial species, many of which have never been cultured (NPL16), making it impossible to a priori predict which, if any, bacteria might influence Tregs.
[0004] In order to develop drugs, dietary supplements, or foods with beneficial immune functions for human use, it is desirable to identify commensal microorganisms that naturally colonize humans and have immunomodulatory properties. Furthermore, since many of the commensal organisms of the human microbiome have not yet been cultivated, it is necessary to develop methods to cultivate them so that they can be produced by conventional industrial fermentation processes and then incorporated into pharmaceutical or food formulations.
[0005] CD4 + The T cells are regulatory T cells, which have been identified as a cell subset that suppresses immunity. +T cells are known to play an important role in maintaining immunological homeostasis, and these cells express the transcription factor Foxp3 (NPL8, 9, 17, and 18). There are many Foxp3-expressing cells in the large intestine, and only Treg cells localized in the large intestine constitutively express high levels of the immunosuppressive cytokine IL-10 (NPL19). CD4 + Foxp3 + Animals in which IL-10 is specifically depleted from cells develop inflammatory bowel disease (NPL20). There is therefore a need to identify human-derived commensal bacterial species capable of potently inducing high levels of IL-10 production in the large intestine by Treg cells and to develop methods for culturing such species, which could be used to enhance immunosuppression and thus potentially for the treatment of inflammatory bowel disease, inflammatory diseases, autoimmune diseases such as allergies, among other diseases and pathologies, or for organ transplantation. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] JJCebra, "Am J Clin Nutr", May 1999, 69, 1046S [Non-Patent Document 2] AJMacpherson, NLHarris, "Nat Rev Immunol", June 2004, 4, 478 [Non-Patent Document 3] JLRound, SKMazmanian, "Nat Rev Immunol", May 2009, 9, 313 [Non-Patent Document 4] D. Bouskra et al., "Nature", November 27, 2008, 456, 507 [Non-Patent Document 5] K. Atarashi et al., "Nature", October 9, 2008, 455, 808 [Non-Patent Document 6] Ivanov, IIら, "Cell Host Microbe", October 16, 2008, 4, 337
Non-licensed Document 7
Non-licensed Document 8
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
Non-licensed Document 16
Non-licensed Document 17
Non-licensed Document 18
[0007] The composition and method of the present invention have been made in consideration of the above-mentioned problems in the technical field. The present specification describes a method for identifying and culturing an intestinal commensal bacterium isolated from a human and inducing, preferably strongly inducing, the proliferation, accumulation, or proliferation and accumulation of regulatory T cells. The present specification describes a composition, also called a bacterial composition, which comprises (1) (a) one or more identified intestinal commensal (human-derived) bacteria; (b) one or more culture supernatants of the bacteria; (c) one or more physiologically active substances derived from the bacteria or one or more culture supernatants; or (d) a combination of any two or three of (a) to (c), and (2) induces the proliferation and / or accumulation of regulatory T cells (Treg cells). Alternatively, the composition comprises (a) one or more identified intestinal commensal (human-derived) bacteria; (b) one or more culture supernatants of the bacteria; or (c) one or more physiologically active substances derived from the bacteria or the culture supernatants, and induces the proliferation and / or accumulation of regulatory T cells. In some embodiments, the composition comprises one or more identified gut commensal (human-derived) bacteria. In some embodiments, the composition comprises culture supernatant of one or more of the bacteria. In some embodiments, the composition comprises one or more bioactive substances derived from the bacteria or the culture supernatant. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are three or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are five or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 17 or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 23 or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 23 or more. In certain embodiments, the bacterial composition induces, preferably strongly induces, the proliferation, accumulation, or proliferation and accumulation of regulatory T cells that produce high levels of immunosuppressive cytokines such as IL-10 in the large intestine (e.g., human large intestine).
[0008] Such bacterial compositions are useful, for example, to enhance immunosuppression and thus treat autoimmune diseases. The bacterial composition comprises as active ingredient at least one organism and / or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum. saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662; culture supernatants of at least one type (one, one or more) of the bacteria described / enumerated herein; biologically active substances derived from the bacteria (one, one or more) described / enumerated herein or any combination of two or three of the above. Alternatively, the bacterial composition comprises as an active ingredient at least one organism or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum. saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662; culture supernatants of at least one type (one, one or more) of the bacteria described / or enumerated herein; bioactive substances derived from the bacteria (one, one or more) described / enumerated herein.
[0009] In some embodiments, the bacterial composition comprises at least one organism selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens ... scindens), Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662. In some embodiments, the bacterial composition comprises a culture supernatant of at least one (one, one or more) bacteria described / enumerated herein. In some embodiments, the bacterial composition comprises a bioactive substance derived from a (one, one or more) bacteria described / enumerated herein. In some embodiments, the one or more bacteria or the one or more bioactive substances derived from the bacteria are three or more. In some embodiments, the one or more bacteria or the one or more bioactive substances derived from the bacteria are five or more. In some embodiments, the one or more bacteria or the one or more bioactive substances derived from the bacteria are 17 or more. .
[0010] In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 23 or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 23 or more. The bacterial composition can include any bacterium, including Clostridium, that comprises DNA comprising a nucleotide sequence having sufficient homology to the sequences provided herein and that exhibits substantially the same effect on regulatory T cells as any one of the following bacteria: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides spp. sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662.
[0011] In some embodiments, the bacteria present in the bacterial composition have at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology to a sequence provided herein, such as, but not limited to, the nucleotide sequences designated herein as OTUs, e.g., those listed on the page after the last Example. In certain embodiments, such bacteria comprise DNA comprising a nucleotide sequence having at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology to one or more DNA sequences named herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, the bacterium comprises DNA comprising a nucleotide sequence having at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology to the DNA of one or more of the following bacteria: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum. saccharolyticum WM1, Bacteroides sp.)MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes cacae caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp.) D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662.
[0012] In certain embodiments, the bacterial composition comprises a bacterium (such as a human-derived bacterium) that comprises DNA comprising a nucleotide sequence having at least 97%, 98% or 99% homology to a sequence provided herein, such as, but not limited to, a nucleotide sequence designated herein as an OTU, such as, for example, a nucleotide sequence listed on the page following the last Example. In certain embodiments, the bacteria in the bacterial composition comprise DNA comprising a nucleotide sequence having at least 97%, 98% or 99% homology to one or more of the DNA sequences named herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, the bacterium comprises DNA comprising a nucleotide sequence having at least 97%, 98% or 99% homology to the DNA of one or more of the following bacteria: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.)MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes cacae caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp.) D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662. All Clostridia bacteria can exist in spore or vegetative forms. [Means for solving the problem]
[0013] As described herein, among the more than 1,000 bacterial species found in the human microbiome, several species are potent inducers of Treg accumulation in the large intestine.
[0014] As also described, most of the bacterial species present in fecal samples from healthy individuals are not capable of stimulating Tregs, whereas species belonging to the genus Clostridium are capable of causing strong induction of Tregs in the large intestine. Furthermore, the inventors obtained in vitro cultures of each of the identified bacterial species and demonstrated that inoculation of mice with the in vitro cultured species also robustly enriched in Tregs in the large intestine. As described herein, the compositions comprise as active ingredients (a) one or more specific species of bacteria belonging to the spore-forming or vegetative genus Clostridia or bacteria containing DNA comprising a nucleotide sequence having at least 90% homology to a sequence provided herein; (b) a culture supernatant of one or more such bacteria; (c) one or more physiologically active substances derived from (a) or (b); or (d) a combination of any two or three of (a), (b) and (c), which induce proliferation and / or accumulation of regulatory T cells (Treg cells) and suppress immune function.
[0015] More specifically: One embodiment is a composition for inducing proliferation, accumulation or both proliferation and accumulation of regulatory T cells, the composition comprising as an active ingredient at least one organism and / or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides spp. sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662; culture supernatants of at least one of the bacteria described / enumerated herein, and biologically active substances derived from the bacteria described / enumerated herein.
[0016] In some embodiments, the active ingredient is one or more of the following bacteria: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens. scindens), Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM14662.
[0017] In some embodiments, the active ingredient is a culture supernatant of one or more bacteria described / listed herein. In some embodiments, the active ingredient is one or more bioactive substances derived from the bacteria described / listed herein. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are three or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are five or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 17 or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 23 or more. In some embodiments, the one or more bacteria or one or more bioactive substances derived from the bacteria are 23 or more.
[0018] The bacterial compositions described herein comprise at least one of the following: one bacterium as described herein; at least one culture supernatant or a portion of such a supernatant obtained from a culture in which one (or more) of said bacteria was present (grown or maintained); one or more bioactive substances derived from one or more bacteria (such as those listed herein), or a combination of any two or three of the above. The term composition / bacterial composition refers to all such combinations.
[0019] The bacteria in the composition may be, for example, Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium syndens, and the like. scindens), Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662 or any bacterium (such as a human-derived bacterium) that contains DNA having at least 90% homology (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology) to the sequences provided herein, including, but not limited to, the nucleotide sequences designated OTUs herein, such as those listed on the page following the last Example.
[0020] In certain embodiments, the bacterium comprises DNA comprising a nucleotide sequence having at least 97%, at least 98% or at least 99% homology to one or more of the DNA sequences named herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, the bacterium comprises DNA comprising a nucleotide sequence having at least 97% (97%, 98%, 99%, 100%) homology to DNA of one or more of the following bacteria: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides spp. sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662.
[0021] In one embodiment, the composition induces regulatory T cells that are transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells. In another embodiment, the composition has an immunosuppressive effect.
[0022] One embodiment is a pharmaceutical composition that induces proliferation, accumulation, or both proliferation and / or accumulation of regulatory T cells and suppresses immune function. The pharmaceutical composition comprises a bacterial composition as described herein and a pharmaceutically acceptable component, such as a carrier, solvent, or diluent. In a particular embodiment, such a pharmaceutical composition comprises (a)(1) one or more types of bacteria belonging to the genus Clostridium as described herein in the spore or vegetative form, (2) a culture supernatant of such bacteria, (3) a physiologically active substance derived therefrom, or (4) a combination of any two or three of (1), (2), and (3), and (b) a pharmaceutically acceptable component, such as a carrier, solvent, or diluent. In a particular embodiment, the (a) is at least one organism or substance selected from the group consisting of Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum. saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662, culture supernatants of one or more of said bacteria, and physiologically active substances derived from one or more of said bacteria. In some embodiments, (a) is at least one organism selected from the group consisting of Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, and the like. scindens), Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM14662.
[0023] In some embodiments, the (1) is a culture supernatant of one or more of the bacteria. In some embodiments, the (1) is a bioactive substance derived from one or more of the bacteria. In some embodiments, the at least one organism or substance is three or more. In some embodiments, the at least one organism or substance is five or more. In some embodiments, the at least one organism or substance is 17 or more. In some embodiments, the at least one organism or substance is 23 or more. In some embodiments, the at least one organism or substance is 23 or more. In another embodiment, the at least one organism or substance is 23. In another embodiment, the (a)(1) is a bacterium (such as a human-derived bacterium) that contains DNA having at least 90% homology (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology) with a sequence provided herein, such as, but not limited to, the nucleotide sequences designated herein as OTUs, for example, listed on the page following the last example. In certain embodiments of the pharmaceutical composition, the bacterium comprises DNA comprising a nucleotide sequence having at least 97%, at least 98% or at least 99% homology to one or more of the DNA sequences named herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, the bacterium in the pharmaceutical composition comprises DNA comprising a nucleotide sequence having at least 97% (97%, 98%, 99%, 100%) homology to DNA of one or more of the following bacteria: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor proutii,plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiformeasparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia coccoides cocoides), Anaerostipes caccae DSM14662.
[0024] The pharmaceutical composition induces the proliferation and / or accumulation of regulatory T cells (Treg cells) and suppresses immune function.
[0025] Also provided are methods of inducing regulatory T cell proliferation, proliferation, or both proliferation and proliferation in an individual (e.g., an individual in need thereof, such as an individual in need of induction of regulatory T cell proliferation and / or proliferation), comprising administering to the individual a bacterial composition as described herein, or a pharmaceutical composition comprising a bacterial composition as described herein. In the method, an individual, which may be a healthy individual or an individual in need of prevention, amelioration or treatment of a pathology or disease (also referred to as an individual in need), is administered Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662; culture supernatants of one or more of said bacteria or one or more components of said culture supernatants; bioactive substances derived from one or more of said bacteria, or combinations of two or three of the above. For example, the compositions described may be administered to individuals in need of treatment, reduction in severity or prevention of diseases or conditions such as autoimmune diseases, inflammatory diseases, allergic diseases and infectious diseases.
[0026] Optionally, administration of the bacterial composition may be in combination with or following treatment with one or more antibiotics.
[0027] Optionally, the administration of the bacterial composition may be combined with the administration of at least one prebiotic substance that selectively favors the growth of the species in the bacterial composition over the growth of other human commensal bacterial species. In one embodiment, the prebiotic substance(s) is, for example, a resistant oligosaccharide. In a particular embodiment, the one or more prebiotic substances are selected from the group consisting of almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose, amylopectin, acetyl-CoA, biotin, beet molasses, yeast extract and resistant starch. Also contemplated herein is a composition comprising the bacterial composition and at least one prebiotic substance.
[0028] The bacterial composition may be administered in combination with an agent selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressants, cyclosporine A, mercaptopurine, azathioprine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, anti-leukotrienes, anticholinergic rhinitis drugs, anticholinergic decongestants, mast cell stabilizers, monoclonal anti-IgE antibodies, vaccines, anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab or etanercept, and combinations thereof. Also described herein are compositions comprising the bacterial composition and at least one agent selected from the group consisting of a corticosteroid, mesalazine, mesalamine, sulfasalazine, a sulfasalazine derivative, an immunosuppressant, cyclosporine A, mercaptopurine, azathioprine, prednisone, methotrexate, an antihistamine, a glucocorticoid, epinephrine, theophylline, sodium cromoglycate, antileukotriene, an anticholinergic rhinitis drug, an anticholinergic decongestant, a mast cell stabilizer, a monoclonal anti-IgE antibody, a vaccine, an anti-TNF inhibitor such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations thereof.
[0029] In another embodiment, the bacterial composition can be used as an adjuvant to improve the efficacy of a vaccine formulation. For example, the bacterial composition can be used as a vaccine adjuvant to prevent or treat an autoimmune or allergic disease. In some embodiments, a method of prevention or treatment is provided, the method comprising administering the bacterial composition and administering a vaccine.
[0030] The degree of induction of proliferation or accumulation of regulatory T cells obtained by administration of the compositions described herein can be evaluated by various methods, such as measuring the number of Foxp3-expressing Tregs in a patient sample (such as a biopsy or blood sample), promotion of IL-10 expression, promotion of CTLA4 expression, promotion of IDO expression, suppression of IL-4 expression, or colonization of the bacterial composition in an individual. The results of such evaluations are used as an indicator that proliferation or accumulation of regulatory T cells has been induced in the individual.
[0031] In one embodiment, administration of the compositions described herein results in the induction of regulatory T cells that are transcription factor Foxp3 positive regulatory T cells or IL-10 producing regulatory T cells.
[0032] The compositions described herein can be administered by a variety of routes, and in one embodiment are administered orally to an individual in need thereof, such as a patient in need thereof. The compositions may be administered in a number of oral forms, such as in spore form (either in a dry powder form or dissolved in a liquid formulation), in an enteric coated capsule, sachet, or in a food matrix such as yogurt or a beverage.
[0033] Also provided are methods of predicting a subject's response to treatment with a composition of the invention (predicting whether the subject will respond to treatment). The method includes (a) obtaining a sample (at least one, one or more) from a patient prior to treatment with a bacterial composition described herein, such as a stool sample or colon biopsy; (b) detecting a bacterial strain selected from the group consisting of Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.(c) determining the percentage or count by measuring or determining the percentage or absolute number in a sample of at least one bacterial species selected from the group consisting of: Bacterium spp. ...
[0034] In some embodiments, the method further comprises (d) administering the bacterial composition to the patient if the percentage or count in the sample taken from the patient is lower than the baseline value. Optionally, the method may further comprise measuring the percentage or absolute number of other commensal species belonging to Clostridium cluster IV and XIVa but not present in the bacterial composition in a patient sample (e.g., a fecal sample or a colon biopsy), where the percentage or absolute number (measurement) is lower than the baseline further indicates that the subject may respond well to administration of the bacterial composition. In some embodiments, the method further comprises administering the bacterial composition to the patient if the percentage or absolute number (measurement) is lower than the baseline. In one embodiment, the patient being evaluated suffers from inflammatory bowel disease or C. difficile infection.
[0035] Also provided is a method of monitoring a subject's response to treatment with a bacterial composition of the invention, comprising: (a) obtaining (at least one) sample, such as a stool sample or colon biopsy, from a patient prior to treatment with a bacterial composition described herein; (b) obtaining (at least one) corresponding sample from the patient after treatment with a bacterial composition described herein; and (c) detecting in the sample obtained in (a) any of Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum ... saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662, and comparing the percentage or absolute number of the at least one bacterial species in the sample obtained in (b) with the percentage or absolute number of the same at least one bacterial species in the sample obtained in (b), wherein a value in the sample obtained in (b) (after treatment with the bacterial composition) that is greater than the value in the sample obtained in (a) (before treatment) is indicative that the subject has responded well to the treatment (e.g., is a positive indication of enhanced immunosuppression in the subject).
[0036] In some embodiments, the method further comprises (d) further administering the bacterial composition to the patient or ceasing administration of the bacterial composition to the patient based on the comparison in (c). Optionally, the method may comprise measuring the proportion or absolute number of other commensal species belonging to Clostridium clusters IV and XIVa but not present in the bacterial composition in the subject's sample, with a post-treatment value greater than the pre-treatment value indicating that the subject has responded well to the treatment. Effect of the Invention
[0037] Efficacy of the compositions and methods described herein The compositions described herein contain as active ingredients selected bacteria belonging to the Clostridia and other bacteria described herein; culture supernatants of such bacteria; physiologically active substances derived from such bacteria; or combinations of two or three of the above, and are excellent at inducing the proliferation or accumulation of regulatory T cells (Treg cells).
[0038] For example, the bacterial composition can be orally ingested in a food or drink or as a nutritional supplement, or a pharmaceutical composition containing the bacterial composition can be administered to suppress the immunity of an individual. The composition of the present invention can be used, for example, to prevent or treat autoimmune diseases, allergic diseases, and infectious diseases, as well as to suppress immune rejection in organ transplants. Furthermore, if a food or drink, such as a health food, contains the composition of the present invention, healthy individuals can easily ingest the composition on a daily basis. As a result, it is possible to induce regulatory T cell proliferation and / or accumulation and improve immune function.
[0039] The compositions described herein provide a natural, long-lasting, patient-friendly and gentle alternative therapy for immune-mediated pathologies. For example, inflammatory bowel disease is currently treated with synthetic drugs that may have severe side effects (such as corticosteroids, TNF inhibitors), cannot be administered orally (such as TNF inhibitors), are inconvenient to administer as pills several times a day (such as mesalazine or sulfasalazine), or are less effective and temporary (such as currently available probiotics, e.g., Lactobacillus GG, Lactobacillus acidophilus, Bifidobacterium longum, etc.). [Brief description of the drawings]
[0040] [Figure 1AB]Figure 1A shows histograms of CD4+ cells taken from the colonic lamina propria (CLPL, left panel) and small intestinal lamina propria (SI LPL, right panel) of GF mice or GF mice colonized with untreated human feces (+huUT, n=4, numbers #A1-#A4) or GF mice colonized with chloroform-treated human feces (+huChloro, n=4, numbers #B1-#B4) and gated by Foxp3 expression. Figure 1B shows histograms of Helios expression in Foxp3+CD4+ cells in the colonic lamina propria (left panel) and small intestinal lamina propria (right panel) of GF mice or GF mice colonized with untreated human feces (+huUT) or GF mice colonized with chloroform-treated human feces (+huChloro). The numbers above the dividing lines in (A) and (B) represent the percentage of the population. [Figure 1C-D] Graphs showing pooled data on Foxp3 expression in CD4+ cells and Helios expression in Foxp3+CD4+ cells in the colonic lamina propria (left panel) and small intestinal lamina propria (right panel) of GF mice or GF mice colonized with untreated human feces (+huUT) or GF mice colonized with chloroform-treated human feces (+huChloro). Circles in (C) and (D) represent individual mice, and error bars represent SD. *P<0.05; **P<0.001, unpaired t-test. [Figure 1E] Representative flow cytometry dot plots of intracellular expression of IL-17 and IFN- in CD4+ cells in the colonic lamina propria (upper panel) and small intestinal lamina propria (lower panel) of GF mice or GF mice colonized with untreated human feces (+huUT) or GF mice colonized with chloroform-treated human feces (+huChloro). Numbers in each quadrant in (E) represent the percentage of the population. [Figure 1FG]Combined data for IL-17 and IFN-expression in CD4+ cells from the colonic (left panel) and small intestinal (right panel) lamina propria of GF mice or GF mice colonized with untreated human feces (+huUT) or GF mice colonized with chloroform-treated human feces (+huChloro), respectively. Each circle in (F, G) represents an individual mouse, and error bars represent SD. *P<0.05; ns, not significant (P>0.05), unpaired t-test. [Diagram 2] Representative plots (A) and combined data (B,C) for Foxp3 expression in CD4+ cells (upper panel in A, left panel in B) or Helios expression in Foxp3+CD4+ cells (lower panel in A, right panel in C) from GF mice and GF mice orally inoculated (once a week for 4 weeks) with a suspension of pre-autoclaved chloroformed human feces. Numbers above the dividing line in (A) represent percentages of the population. Circles in (B,C) represent individual mice and error bars represent SD. ns, not significant (P>0.05), unpaired t-test. [Diagram 3] Representative plots (A, data from mouse #C4 shown here) and combined data (B) of Foxp3 expression in CD4+ cells of colonic and small intestinal lamina propria lymphocytes from GF mice and GF mice orally inoculated with chloroform-treated human feces (+huChloro, n=7, numbers #C1-#C7). Numbers above the dividing lines in (A) represent percentages of the population. Each circle in (B) represents an individual mouse, and error bars represent SD. **P<0.001, unpaired t-test. [Figure 4]Representative plots (A) and combined data (B) of Foxp3 expression in CD4+ cells in the colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL) of GF mice (numbered #D1-#D6) cohabited with ex-GF mice #C6 and #C7 colonized with chloroform-treated human feces. Numbers above the dividing line in (A) represent percentages of the population. Circles in (B) represent individual mice, error bars represent SD. **P<0.001, unpaired t-test. [Diagram 5] Representative plots and integrated data for Foxp3 expression in CD4+ cells (A, B) and Helios expression in Foxp3+CD4+ cells in the colonic lamina propria (C LPL) and intestinal lamina propria (SI LPL) of GF mice, GF mice inoculated with 2000-fold diluted #C4 mouse fecal suspension (+×2000, n=4, #E1-#E4), or GF mice inoculated with 20000-fold diluted #C4 mouse fecal suspension (+×20000, n=8, #F1-#F8). The numbers above the dividing line in (A) represent the percentage of the population. Each circle in (B) and (C) represents an individual mouse, and error bars represent SD. *P<0.05; **P<0.001, unpaired t-test. [Figure 6] Representative plots (A, B) and pooled data (C, D) for Foxp3 expression in CD4+ cells (A, C) or Helios expression in Foxp3+CD4+ cells (B, D) in the colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL) of GF mice and GF mice inoculated with fecal suspensions from #F3 (n=5), #F7 (n=4), or #F8 (n=4) mice. Numbers above the dividing lines in (A) and (B) represent percentages of the population. Circles in (C) and (D) represent individual mice, and error bars represent SD. *P<0.05; **P<0.001, unpaired t-test. [Figure 7]Representative plots (A) and combined data (B,C) of Foxp3 expression in CD4+ cells or Helios expression in Foxp3+CD4+ cells from GF mice (n=4, no. #J1-#J4) inoculated with three bacterial strains isolated from the cecal contents of GF and #F8 mice. Numbers above the dividing line in (A) represent percentages of the population. Each circle in (B) and (C) represents an individual mouse, and error bars represent SD. ns, not significant (P>0.05), unpaired t-test. [Figure 8] Figure 1 shows the relative abundance of OTUs with the same closest relative species in each cecal sample (bacterial DNA was extracted from the cecal contents of mice #A1, #C4, #F8, #G2, #H3, #I3, #J3, and #K3, and is shown as a bar). The total number of OTUs detected in each sample is shown below the bar. The name of the OTU detected in sample #H3, #I3, or #K3, its closest relative species, and its similarity to the closest relative species are shown in the table on the right. [Figure 9] Representative plots (A) and combined data (B,C) for Foxp3 expression in CD4+ cells (A,B) or Helios expression in Foxp3+CD4+ cells (A,C) in the colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL) of GF mice (n=4, no. #K1-#K4) inoculated with bacteria recovered from culture plates of cecal contents of GF and #G2 mice. Numbers above the dividing line in (A) represent percentages of the population. Circles in (B) and (C) represent individual mice, error bars represent SD. *P<0.05; **P<0.001, unpaired t-test. [Figure 10]Representative plots (A) and combined data (B,C) for Foxp3 expression in CD4+ cells or Helios expression in Foxp3+CD4+ cells in the colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL) of GF mice and GF mice inoculated with a mixture of 23 strains isolated and listed in Table 2 (23mix). Numbers above the dividing line in (A) represent percentages of the population. Circles in (B) and (C) represent individual mice, error bars represent SD. *P<0.05; **P<0.001, unpaired t-test. [Figure 11] Representative plots of Foxp3+CD4+ cell accumulation in adult GF mice inoculated with 2×104-2×107 diluted cecal samples from +huChlo mice. Experiments were performed more than three times. Error bars represent SD. **P<0.01, *P<0.05 as calculated by Student's t-test. [Figure 12] Representative plots of Foxp3+CD4+ cell accumulation in the colon of adult GF mice inoculated with a mixture of 23 strains (23-mix) isolated and listed in Table 2, adult GF mice inoculated with chloroform-treated human feces (+huChlo), and adult GF mice inoculated with Faecalibacterium prausnitzii (+Faecali). Error bars represent SD. **P<0.01 calculated by Student's t-test. [Figure 13] FIG. 13 shows representative plots of Foxp3+CD4+ cell accumulation in adult GF mice inoculated with the cecal contents of +2×104 mice for the second time (+2×104-re) and adult GF mice inoculated with the cecal contents of the same mice for the third time (+2×104-re-re), and adult GF mice inoculated with a cecal sample from a +2×104 mouse diluted 2×104 times (+(2×104)2). [Figure 14]Figure 1 shows the results of 16s rDNA pyrosequencing of the cecal contents of defined mice (+hu, +huChlo, +2x104, +2x104-re, (+2x104)2, +23-, mix) using a 454 sequencer. The relative abundance (%) of OTUs in the cecal bacterial community of each mouse is shown, as well as the closest relative strains in the database and the corresponding isolate numbers for the indicated OTUs. [Figure 15] Representative plots of Foxp3+CD4+ cell accumulation in the colon of adult IQI, BALB and B6 GF mice inoculated with a mixture of 17 strains isolated and shown in Table 4 (17-mix). **P<0.01 as calculated by Student's t-test. [Figure 16] FIG. 1 shows representative plots of Foxp3+CD4+ cell accumulation in adult IQI GF mice monocolonized with each of the 17 strains (17-mix) listed in Table 4. [Figure 17] Representative plots of Foxp3+CD4+ cell accumulation in adult IQI GF mice colonized with 3-mix, 5mix-A, 5-mix-B, 5-mix-C or 17-mix as listed in Table 4. Circles represent individual mice. Experiments were performed more than three times with similar results. Error bars represent SD. **P<0.01, *P<0.05, ns, not significant, calculated by Student's t-test. [Figure 18] Representative plots of Foxp3+CD4+ cell accumulation in adult SPF mice repeatedly inoculated with 17-mix (SPF+17mix; n=5) or control (SPF+cont; n=6). **P<0.01 as calculated by Student's t-test. [Figure 19] Figure 1 shows the effect of 17-mix vaccination on diarrhea OVA model measured by qualitative diarrhea score.*P<0.05 calculated by Student's t-test. [Figure 20] FIG. 1 shows the survival rate of adult mice exposed to trinitrobenzene sulfonic acid (TNBS), a drug used in experimental models of colitis, and then inoculated with a mixture of 17 strains (17-mix) listed in Table 4. [Figure 21] Figure 1 shows the relative abundance of each of the 17-mix strains in the human fecal microbiota of ulcerative colitis and healthy subjects. The genomes of the 17 strains were compared to the reads from 15 healthy and 20 ulcerative colitis subjects published in the MetaHIT database. The average number of mapped reads in the healthy and UC groups for each of the 17 genomes is shown. Error bars represent SEM. *P<0.05 calculated by Student's t-test.
[0041] Brief explanation of the table Table 1 shows the number of detected reads and the closest relatives obtained for each OTU from the amplification of the 16s rRNA coding gene of bacterial DNA extracted from the cecal contents of mice #A1, #C4, #F8, #G2, #H3, #I3, #J3 and #K3 and the classification (classification based on sequence similarity using BLAST, >97% identity with sequences in nucleic acid databases) of the sequences (3400 reads for each sample) by PCR metasequencing.
[0042] Table 2 shows the closest relatives to known species, the maximum similarity to the closest relatives, classification in the Clostridiaceae cluster, the mouse ID of origin, and the medium used for isolation for each of the 17 strains isolated from the cecal contents of mice #F8, #G2, #I1, and #K3 using BL agar or EG agar plates.
[0043] Table 3 shows the closest relatives among known species, the maximum similarity to the closest relatives, the databases used for BLAST search, and the similarity between strains for each of the 31 strains isolated from the cecal contents of mice #F8, #G2, #I1, and #K3 using BL agar or EG agar plates.
[0044] Table 4 shows the results of 16S rDNA analysis for each of the 31 isolated strains. Bacterial DNA was isolated from each of the 31 strains, and the 16S rDNA of the isolates was amplified by colony PCR. Each amplified DNA was purified, sequenced, and sequenced using the ClustalW software program. Based on the sequence of the 16S rDNA of each strain, its closest relatives, % similarity to the closest relatives, and similarity to other strains are shown. Strains that were included in 23-mix, 17-mix, 5-mixA, 5-mixB, 5-mixC, and 3-mix are marked in the right column. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] <Composition having the effect of inducing proliferation or accumulation of regulatory T cells> Described herein are compositions that induce regulatory T cell proliferation, recruitment, or both regulatory T cell proliferation and recruitment. The composition may include one or more of the following active ingredients: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium sindens. scindens), Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.(At least one, one or more) organisms selected from the group consisting of Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662, culture supernatants of one or more of said bacteria, components of media in which the (at least one, one or more) bacteria described herein are grown, bioactive substances derived from the (at least one, one or more) bacteria described herein; and (at least one, one or more) bacteria comprising DNA comprising a nucleotide sequence having at least 97% homology to the nucleotide sequence of any of the bacterial species DNA described herein, such as the bacterial species described above. The bacteria described herein have been isolated from human fecal samples using the methods outlined in Examples 19-28.
[0046] The term "regulatory T cells" refers to T cells that suppress abnormal or excessive immune responses and play a role in immune tolerance. Regulatory T cells are usually transcription factor Foxp3-positive CD4-positive T cells. The regulatory T cells of the present invention also include transcription factor Foxp3-negative regulatory T cells, which are CD4-positive T cells that produce IL-10.
[0047] The term "inducing proliferation or accumulation of regulatory T cells" refers to the action of inducing differentiation of immature T cells into regulatory T cells, which leads to proliferation and / or accumulation of regulatory T cells. Furthermore, the meaning of the term "inducing proliferation or accumulation of regulatory T cells" includes in vivo action, in vitro action, and ex vivo action. All of the following actions are included: the action of inducing proliferation or accumulation of regulatory T cells in vivo by administration or ingestion of the bacterium belonging to the genus Clostridia, the culture supernatant or supernatant component (one or more) of the bacterium, or a physiologically active substance derived from the bacterium; the action of inducing proliferation or accumulation of cultured regulatory T cells by allowing the bacterium belonging to the genus Clostridia, the culture supernatant or supernatant component (one or more) of the bacterium, or a physiologically active substance derived from the bacterium to act on the cultured regulatory T cells; and the action of inducing proliferation or accumulation of regulatory T cells by allowing the bacterium belonging to the genus Clostridia, the culture supernatant or supernatant component (one or more) of the bacterium, or a physiologically active substance derived from the bacterium to act on the regulatory T cells that are to be introduced into a living organism, such as the living organism from which the bacterium was taken or another living organism, after being taken from the living organism. The action of inducing proliferation or accumulation of regulatory T cells can be evaluated, for example, as follows. Specifically, the above-mentioned bacterium belonging to the genus Clostridium, the culture supernatant or supernatant component (single or multiple) of the bacterium, or a physiologically active substance derived from the bacterium is orally administered to an experimental animal such as a germ-free mouse, and then CD4-positive cells in the large intestine are isolated and the proportion of regulatory T cells contained in the cells is measured by flow cytometry (see Example 7).
[0048] The regulatory T cells whose proliferation or accumulation is induced by the composition of the present invention are preferably transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells.
[0049] In the present invention, "human-derived bacteria" refers to a bacterial species isolated from a fecal sample or digestive tract biopsy taken from a human individual, or a bacterial species that originates from (e.g., is descended from) a bacterium isolated from a fecal sample or digestive tract biopsy taken from a human. For example, the bacterial species may have already been isolated from a fecal sample or digestive tract biopsy taken from a human and cultured for a sufficient time to produce progeny. The progeny can then be further cultured or frozen. Human-derived bacteria are natural commensals that inhabit the digestive tract of human individuals, preferably healthy human individuals.
[0050] In the present invention, the term "Clostridium" (such as in "composition containing bacteria belonging to the genus Clostridia") refers to a type of gram-positive obligate anaerobic bacteria belonging to the phylum Firmicutes and capable of forming spores. It is important to note that although most of this type of bacteria are currently included in the order Clostridiales, this classification is still based in part on older methods and may be redefined in the future as new advances in sequencing technology allow for the sequencing of the entire genome of this type of bacteria. Table 2 summarizes the classification of 17 abundant species belonging to the genus Clostridia that the inventors identified as potent inducers of Tregs and cultured in vitro. All of the species listed here are classified into the family Clostridiaceae according to current classification rules and belong to clusters IV, XIVa, XVI and XVIII.
[0051] The compositions of the present invention may contain any one of the above bacterial strains alone (one strain only), but two or more strains of the bacteria may be used together. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 of the strains listed in Table 2 or Table 4 may be used together in any combination to affect regulatory T cells. In some embodiments, a mixture of 23, 17, 5, or 3 strains listed in Table 4 may be used together (and administered in one or more compositions) to affect regulatory T cells. In some embodiments, the following strains may be combined (the composition may comprise): strain 1 (OTU136, closely related to Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 3 (OTU221, closely related to Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 4 (OTU9, closely related to Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 5 (OTU296, closely related to Clostridium scindens), as listed in Table 4. scindens), Lachnospiraceae bacterium 5_1_57FAA), strain 6 (OTU21, closely related species: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 7 (OUT166, closely related species: Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 8 (OTU73, closely related species: cf. Clostridium sp.) MLG055, Erysipelotrichaceae bacterium 2_2_44A), strain 9 (OTU174, closely related species: Clostridium indolis, Anaerostipes caccae DSM14662), strain 10 (OTU166, closely related species: Clostridium bolteae, Clostridium bolteae ATCC BAA-613), strain 12 (OTU55, closely related species: Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 13 (OTU337, closely related species: Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241), strain 14 (OTU314, closely related species: Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA), strain 15 (OTU195, closely related species: Clostridium lavalense, Clostridium asparagiforme DSM15981), strain 16 (OTU306, closely related species: Clostridium symbiosum symbiosum, Clostridium symbiosum WAL-14163), strain 18 (OTU46, closely related species: Clostridium ramosum, Clostridium ramosum), strain 21 (OTU87, closely related species: Eubacterium contortum, Clostridium sp.) D5), strain 23 (OTU152, closest related species: Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 24 (OTU253, closest related species: Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes), strain 25 (OTU259, closest related species: Eubacterium contortum, Clostridium sp. D5), strain 26 (OTU281, closest related species: Clostridium scindens), Lachnospiraceae bacterium 5_1_57FAA), strain 27 (OTU288, closely related species: Lachnospiraceae bacterium A4, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 28 (OTU344, closely related species: Clostridium sp. 316002 / 08, Clostridiales bacterium 1_7_47FAA), and strain 29 (OTU359, closely related species: Lachnospiraceae bacterium A4, Lachnospiraceae bacterium 3_1_57FAA_CT1).
[0052] In some embodiments, the following strains may be combined (the composition comprises): strain 1 (OTU136, closely related to Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 3 (OTU221, closely related to Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 4 (OTU9, closely related to Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 6 (OTU21, closely related to Blautia coccoides), strain 7 (OTU22, closely related to Blautia coccoides), strain 8 (OTU22, closely related to Blautia coccoides), strain 9 (OTU22, closely related to Blautia coccoides), strain 10 (OTU22, closely related to Blautia coccoides), strain 11 (OTU22, closely related to Blautia coccoides), strain 12 (OTU22, closely related to Blautia coccoides), strain 13 (OTU22, closely related to Blautia coccoides), strain 14 (OTU22, closely related to Blautia coccoides), strain 15 (OTU22, closely related to Blautia coccoides), strain 16 (OTU22, closely related to Blautia coccoides), strain 17 (OTU22, closely related to Blautia coccoides), strain 19 (OTU22, closely related to Blautia coccoides), strain 20 (OTU22, closely related to Blautia coccoides), strain 21 (OTU22, closely related to Blautia coccoides), strain 22 (OTU22, closely related to Blautia coccoides), strain 23 (OTU22, closely related to Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 2979 coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 7 (OUT166, closely related species: Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 8 (OTU73, closely related species: cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A), strain 9 (OTU174, closely related species: Clostridium indolis, Anaerostipes caccae DSM14662), strain 13 (OTU337, closely related species: Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241), strain 14 (OTU314, closely related species: Ruminococcus sp.) ID8, Lachnospiraceae bacterium 2_1_46FAA), strain 15 (OTU195, Closely related species: Clostridium lavalense, Clostridium asparagiforme DSM15981), strain 16 (OTU306, Closely related species: Clostridium symbiosum, Clostridium symbiosum WAL-14163), strain 18 (OTU46, Closely related species: Clostridium ramosum, Clostridium ramosum), strain 21 (OTU87, Closely related species: Eubacterium contortum, Clostridium sp. D5), strain 26 (OTU281, closely related to Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA), strain 27 (OTU288, closely related to Lachnospiraceae bacterium A4, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 28 (OTU344, closely related to Clostridium sp. 316002 / 08, Clostridiales bacterium 1_7_47FAA), and strain 29 (OTU359, closely related to Lachnospiraceae bacterium) A4, Lachnospiraceae bacterium) 3_1_57FAA_CT1).
[0053] In some embodiments, the following strains may be combined (the composition may comprise): strain 1 (OTU136, closely related to Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 4 (OTU9, closely related to Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 16 (OTU306, closely related to Clostridium symbiosum, Clostridium symbiosum WAL-14163), strain 27 (OTU288, closely related to Lachnospiraceae) as listed in Table 4. bacterium A4, Lachnospiraceae bacterium 3_1_57FAA_CT1), and strain 29 (OTU359, closely related species: Lachnospiraceae bacterium A4, Lachnospiraceae bacterium 3_1_57FAA_CT1).In some embodiments, the following strains can be combined: strain 6 (OTU21, closely related: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 8 (OTU73, closely related: cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A), strain 13 (OTU337, closely related: Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241), strain 14 (OTU314, closely related: Ruminococcus sp.) ID8, Lachnospiraceae bacterium 2_1_46FAA), and strain 26 (OTU281, closely related species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA).In some embodiments, the following strains can be combined: strain 3 (OTU221, closely related to Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 7 (OUT166, closely related to Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 9 (OTU174, closely related to Clostridium indolis, Anaerostipes caccae DSM14662), strain 15 (OTU195, closely related to Clostridium labarensis DSM14662), strain 20 (OTU206, closely related to Clostridium labarensis DSM14662), and strain 21 (OTU222, closely related to Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), as listed in Table 4. lavalense), Clostridium asparagiforme DSM15981, and strain 28 (OTU344, closely related to Clostridium sp. 316002 / 08 and Clostridiales bacterium 1_7_47FAA). In some embodiments, the following strains can be combined: strain 1 (OTU136, closely related to Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 2 (OTU46, closely related to Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799) and strain 3 (OTU221, closely related to Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799) as listed in Table 4.
[0054] By using a combination of multiple strains of the above bacterial species, preferably those belonging to Clostridium cluster XIVa or cluster IV, it is possible to exert an excellent effect on regulatory T cells. In addition to the bacteria belonging to cluster XIVa and cluster IV, Clostridium ramosum, Clostridium saccharogumia (belonging to cluster XVIII) and cf. Clostridium sp. MLG055 (belonging to cluster XVI) can be used. When using more than one strain of bacteria (e.g., one or more strains belonging to cluster XIVa, one or more strains belonging to cluster IV, one or more strains belonging to cluster XVIII or XVI, or any combination of the above), the number and ratio of the strains used can be various. The numbers and ratios used can be determined based on various factors (e.g., the desired effect, such as inducing or inhibiting proliferation or accumulation of regulatory T cells; the disease or condition to be treated, prevented or reduced in severity; the age or sex of the recipient; the typical amount of the strain in a healthy human).
[0055] The strains may be present in a single composition, in which case the strains can be ingested or absorbed simultaneously (in a single composition), or the strains may be present in two or more compositions (e.g., each in a separate composition), in which case the strains can be ingested separately, or the compositions can be combined and the resulting combination (combination composition) ingested or absorbed. Any number or combination of strains that is effective (e.g., any number from 1 to 22, such as 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3, 1 to 2, and any number in between, or 1 to 23, such as 1 to 23, 3 to 23, 5 to 23, 1 to 20, 1 to 17, 3 to 17, 5 to 17, 1 to 15, 1 to 10, 1 to 5, 3 to 5, 1 to 3, 1 to 2, and any number in between) can be administered.
[0056] In certain embodiments of the invention, a combination of some or all of the 22 or 23 strains described in this disclosure (e.g., the 23 strains in Example 32 and Table 4) is used. For example, any number of strains including at least 1, 2 or more, 3, 3 or more, 4, 4 or more, 5, 5 or more, 6, 6 or more of the 22 or 23 strains described can be used. In some embodiments, a specific combination of 3, 5, 17 or 23 strains described in Table 4 can be used (the composition includes a combination of 3, 5, 17 or 23 strains described in Table 4). The strains listed here can be used in combination with each other or in combination with strains not described in the cited literature.
[0057] Cells of bacteria belonging to the genus Clostridia, particularly those described herein, can be used in either spore or vegetative form. From the viewpoints of stability under high temperature and pressure conditions, long shelf life, ease of handling, resistance to antibiotics, and lack of need for cold chain storage and distribution, the bacteria may be preferably in spore form. Conversely, the bacteria can be produced (and subsequently administered) in vegetative cells in terms of compliance with the instructions of certain manufacturing organizations, whose facilities cannot be tolerated to be contaminated with spores.
[0058] The term "biologically active substance derived from bacteria belonging to the genus Clostridia" includes substances contained in the bacteria, secretory products of the bacteria, and metabolic products of the bacteria. Such a bioactive substance can be identified by purifying the active ingredient from the bacteria, its culture supernatant, or the intestinal contents of a mouse colonized only with bacteria belonging to the genus Clostridia by known purification methods.
[0059] "Chloroform treatment" of a fecal sample collected from a human refers to a method for isolating bacteria present in a fecal sample and capable of forming spores, and is not particularly limited as long as the spore-forming fraction is obtained by treating human feces with chloroform (e.g., 3% chloroform) and has the effect of inducing proliferation or accumulation of regulatory T cells, including mammalian regulatory T cells such as mouse regulatory T cells and human regulatory T cells.
[0060] When the above-mentioned "bacteria belonging to the genus Clostridium" is cultured in a medium, the bacteria release substances contained in the bacteria, secretory products and metabolic products produced by the bacteria. The meaning of "bacterial culture supernatant" which is an active ingredient of the composition of the present invention includes such substances, secretory products and metabolic products. The culture supernatant is not particularly limited as long as it has the effect of inducing the proliferation or accumulation of regulatory T cells. Examples of the culture supernatant include the protein fraction of the culture supernatant, the polysaccharide fraction of the culture supernatant, the lipid fraction of the culture supernatant and the low molecular weight metabolic product fraction of the culture supernatant.
[0061] The bacterial composition may be administered in the form of a pharmaceutical composition, a nutritional supplement, or a food or drink (which may be animal feed), or may be used as a reagent in model animal experiments. The pharmaceutical composition, the nutritional supplement, the food or drink, and the reagent induce the proliferation or accumulation of regulatory T cells. In the examples described herein, it has been revealed that regulatory T cells (Treg cells) induced by bacteria belonging to the genus Clostridium suppress the proliferation of effector T cells. The composition of the present invention can be suitably used as a composition having an immunosuppressive effect. The immunosuppressive effect can be evaluated, for example, as follows. Regulatory T cells isolated from an experimental animal such as a mouse to which the composition of the present invention has been orally administered are compared with effector T cells (CD4 + CD25 - cells) and increase their proliferation ability [ 3 The amount of [H]-thymidine incorporation is measured as an indicator (see Example 14).
[0062] The bacterial compositions of the invention can be used, for example, as pharmaceutical compositions for preventing or treating (reducing partially or fully the adverse effects of) an inflammatory disease such as an autoimmune disease, such as chronic inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or Hashimoto's disease; an allergic disease, such as food allergy, hay fever, or asthma; an infectious disease, such as infection with Clostridium difficile; a TNF-mediated inflammatory disease (e.g., an inflammatory disease of the gastrointestinal tract, such as pouchitis, an inflammatory condition of the cardiovascular system, such as atherosclerosis, or an inflammatory lung disease, such as chronic obstructive pulmonary disease); as pharmaceutical compositions for inhibiting rejection in situations, such as organ transplantation, where tissue rejection may occur; as a dietary supplement, food or drink, to improve immune function; or as a reagent to inhibit the proliferation or function of effector T cells.
[0063] Further specific examples of target diseases for which the composition is useful for treating (reducing or preventing adverse effects of) include autoimmune diseases, allergic diseases, infectious diseases, and rejection reactions in organ transplants, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, sprue, autoimmune arthritis, rheumatoid arthritis, type 1 diabetes, multiple sclerosis, graft-versus-host rejection following bone marrow transplantation, osteoarthritis, juvenile chronic arthritis, Lyme disease arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, insulin-dependent diabetes mellitus, thyroiditis, asthma, psoriasis, scleroderma dermatitis, and the like. scleroderma), atopic dermatitis, graft-versus-host rejection, acute or chronic immune disorders associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki disease, Graves' disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schelein purpura, microscopic vasculitis of the kidney, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, septic syndrome, cachexia, AIDS (acquired immune deficiency syndrome), acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, polyglandular deficiency syndrome type 1, polyglandular deficiency syndrome type 2, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, chlamydial infection infectious diseases, arthropathy due to Yersinia or Salmonella infection, spondyloarthropathy, atherosclerosis / arteriosclerosis, allergic colitis, atopic allergies, food allergies (e.g., peanut allergy, nut allergy, egg allergy, milk allergy, soy allergy, wheat allergy, seafood allergy, shellfish allergy or sesame allergy, etc.), autoimmune bullous diseases, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune hemolytic anemia, Coombs test positive hemolytic anemia, acquired pernicious anemia, juvenile pernicious anemia, myosyelitis / Royal Free disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, idiopathic autoimmune hepatitis, acquired immune deficiency syndrome, acquired immune deficiency-related diseases, hepatitis C, common variable immunodeficiency (common variable hypogammaglobulinemia), dilated cardiomyopathy, fibrotic lung disease, idiopathic fibrosing alveolitis,Postinflammatory interstitial pneumonia, interstitial pneumonia, connective tissue disease interstitial lung disease, mixed connective tissue disease lung disease, systemic sclerosis interstitial lung disease, rheumatoid arthritis interstitial lung disease, systemic lupus erythematosus lung disease, dermatomyositis / polymyositis lung disease, Sjogren's disease lung disease, ankylosing spondylitis lung disease, vasculitic diffuse lung disease, hemosiderosis lung disease, drug-induced interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrate lung disease, postinfectious interstitial pneumonia, Gouty arthritis, autoimmune hepatitis, autoimmune hepatitis type 1 (classical autoimmune or lupoid hepatitis), autoimmune hepatitis type 2 (anti-LKM1 antibody hepatitis), autoimmune hypoglycemia, type B insulin resistance due to acanthosis nigricans, hypoparathyroidism, immune disorders associated with organ transplantation, chronic immune disorders associated with organ transplantation, osteoarthritis, primary sclerosing cholangitis, idiopathic leukopenia, autoimmune neutropenia, renal disease NOS, glomerulonephritis, microscopic vasculitis in the kidney, Discoid lupus erythematosus, idiopathic male infertility or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), insulin-dependent diabetes mellitus, sympathetic ophthalmia, connective tissue disease with pulmonary hypertension, Goodpasture's syndrome, pulmonary manifestations of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu's disease / arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goiter thyroiditis Hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxedema, phacogenic uveitis, primary vasculitis, vitiligo, allergic rhinitis (pollen allergy), anaphylaxis, pet allergy, latex allergy, drug allergy, allergic rhinitis conjunctivitis, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic gastroenteritis, cutaneous erythmatosus, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic gastroenteritis, and diarrhea.
[0064] Other examples of disease of interest that the compositions are useful for treating include immunopathology associated with colon cancer, cystic fibrosis, celiac disease, type 2 diabetes, and autism, which are characterized by a reduction in Clostridium cluster IV and XIV in the gastrointestinal microbiota.
[0065] The compositions described herein can also be used as pharmaceutical compositions for preventing or treating infectious diseases in individuals whose resistance to infectious diseases is impaired, for example, due to excessive immune inflammation or damage caused by changes in the patient's microbiome. Examples of infectious pathogens that impair the maintenance or restoration of host homeostasis and result in such immunopathological tissue damage include Salmonella, Shigella, Clostridium difficile, Mycobacterium (causing tuberculosis), Protozoa (causing malaria), Filarial nematodes (causing filariasis), Schistosoma (causing schistosomiasis), Toxoplasma (causing toxoplasmosis), Leishmania (causing leishmaniasis), HCV and HBC (causing hepatitis C and hepatitis B), and herpes simplex virus (causing herpes).
[0066] Pharmaceutical preparations can be prepared from the bacterial compositions described by methods known to those skilled in the art. For example, the compositions can be used orally or parenterally in the form of capsules, tablets, pills, sachets, liquids, powders, granules, fine granules, film-coated preparations, pellets, lozenges, sublingual preparations, chewable preparations, buccal preparations, pastes, syrups, suspensions, elixirs, emulsions, liniments, ointments, plasters, poultices, transdermal preparations, lotions, inhalants, aerosols, injections, suppositories, etc.
[0067] To prepare the preparations listed above, the bacterial composition can be used in appropriate combination with a pharma- ceutically acceptable carrier or one or more of the following that can be ingested in foods, beverages, etc.: sterile water, saline, vegetable oil, solvent, base, emulsifier, suspending agent, surfactant, stabilizer, flavoring agent, fragrance, excipient, vehicle, preservative, binder, diluent, isotonicity agent, soothing agent, bulking agent, disintegrant, buffer, coating agent, lubricant, colorant, sweetener, viscosity agent, flavoring agent, solubilizing agent, and other additives.
[0068] The pharmaceutical product or pharmaceutical formulation, particularly the pharmaceutical product for oral administration, contains an additional composition that allows the composition of the present invention to be efficiently delivered to the large intestine in order to more efficiently induce proliferation or accumulation of regulatory T cells in the large intestine. Various compositions that allow the bacterial composition to be delivered to the large intestine can be used. Examples include pH-sensitive compositions, more specifically, buffered pouch formulations or enteric polymers that release their contents when the pH becomes alkaline after the enteric polymer passes through the stomach. When a pH-sensitive composition is used to formulate a pharmaceutical product, the pH-sensitive composition is preferably a polymer with a pH threshold of about 6.8 to about 7.5 at which the composition degrades. This numerical range is suitable for delivery to the large intestine because it is the range in which the pH shifts to the alkaline side in the distal part of the stomach.
[0069] Another embodiment of a pharmaceutical useful for delivering the bacterial composition to the large intestine includes a composition that ensures delivery to the large intestine by delaying the release of the contents (e.g., the bacterial composition) by approximately 3-5 hours, which corresponds to the small intestine transit time. In one embodiment of a pharmaceutical product with delayed release, a hydrogel is used as a shell. The hydrogel hydrates and expands upon contact with gastrointestinal fluids, resulting in efficient dissolution of the contents (primarily released in the large intestine). A delayed release dosage unit includes a drug-containing composition having a material that coats or selectively coats the drug or active pharmaceutical ingredient to be administered. Examples of such selective coating materials include biodegradable polymers, slowly hydrolyzable polymers, slowly water-soluble polymers, and / or enzymatically degradable polymers. A large number of coating materials are available that provide efficient delayed release, including cellulosic polymers such as hydroxypropylcellulose, acrylic polymers and copolymers such as methacrylic acid polymers and copolymers, and vinyl polymers and copolymers such as polyvinylpyrrolidone.
[0070] Compositions that enable delivery to the large intestine further include bioadhesive compositions that specifically adhere to the colonic mucosa (e.g., the polymers described in U.S. Pat. No. 6,368,586) and compositions that incorporate protease inhibitors to protect biological agents from degradation by proteolytic enzyme activity, particularly in the gastrointestinal tract.
[0071] Systems enabling delivery to the large intestine include, for example, pressure change-triggered delivery systems to the large intestine, such as those that release contents by utilizing pressure changes in the distal part of the stomach resulting from gas production by bacterial fermentation. A non-limiting example of such a system is a capsule in which the contents are dispersed in a suppository base and coated with a hydrophobic polymer (e.g., ethyl cellulose).
[0072] Another example of a system that allows delivery to the large intestine is a system for delivering compositions to the large intestine that are specifically degraded by enzymes present in the large intestine (e.g., carbohydrate hydrolases or carbohydrate reductases).Specific examples of such systems include, but are not limited to, systems that use dietary components such as non-starch polysaccharides, amylose, xanthan gum, and azopolymers.
[0073] When the bacterial composition is used as a medicine, it may be used in combination with a known pharmaceutical composition used for immunosuppression. In some embodiments, the medicine may include both the bacterial composition and a known pharmaceutical composition. Such a known pharmaceutical composition is not particularly limited, and may be at least one therapeutic composition selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressants, cyclosporine A, mercaptopurine, azathioprine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, anti-leukotrienes, anticholinergic rhinitis drugs, anticholinergic decongestants, mast cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably vaccines used in vaccination with gradually increasing amounts of allergens), infliximab, adalimumab, certolizumab pegol, golimumab, or anti-TNF inhibitors such as etanercept, and combinations thereof. The therapeutic compositions provided herein are preferably used in combination with the bacterial compositions described herein, which may also be used as adjuvants to improve the efficacy of vaccine formulations, such as vaccines for the prevention or treatment of autoimmune or allergic diseases.
[0074] The bacterial composition can be used as food and drink, for example, health food and drink, food and drink for infants, food and drink for specific groups including pregnant women, athletes, and the elderly, functional food and drink, beverage, food and drink for specified health uses, nutritional supplements, food and drink for the sick, or animal feed, etc. Specific examples of food and drink include various beverages such as juice, soft drinks, tea drinks, energy drinks, jelly-like drinks, and functional drinks; alcoholic beverages such as beer; carbohydrate-containing foods such as rice, noodles, bread, and pasta; paste products such as fish ham, sausage, and fish paste products; retort products such as curry, thickened food, and Chinese soup; soups; dairy products such as milk, milk drinks, ice cream, cheese, and yogurt; fermented products such as miso, yogurt, fermented drinks, and pickles; bean products; Western confectionery such as biscuits and cookies, Japanese confectionery such as buns and yokan, various confectionery such as candies, gums, gummy candies, jellies, and puddings; instant foods such as instant soup and instant miso soup, and microwaveable foods. Further examples include health foods and beverages prepared in the form of powder, granules, tablets, capsules, liquid, paste, or jelly. The composition of the present invention can be used for animals including humans, but there is no particular limitation on animals other than humans, and it can be used for various livestock, poultry, pets, laboratory animals, etc. Specific examples include, but are not limited to, pigs, cows, horses, sheep, goats, chickens, ducks, ostriches, ducks, dogs, cats, rabbits, hamsters, mice, rats, monkeys, etc.
[0075] Without wishing to be bound by theory, individuals relatively rich in bacteria belonging to the Firmicutes group (the group to which Clostridium clusters IV and XIVa belong) gain more weight than individuals relatively rich in bacteria belonging to the Bacteroides group. The bacterial composition can regulate nutrient absorption and improve feed efficiency. In this respect, the bacterial composition can be used to promote weight gain or to make efficient animal feed. Diseases and conditions in which weight gain is beneficial include, for example, starvation, cancer, AIDS, gastrointestinal disorders (e.g., celiac disease, peptic ulcer, inflammatory bowel disease (Crohn's disease and ulcerative colitis), pancreatitis, gastritis, diarrhea), hyperthyroidism, infectious diseases, kidney disease, heart disease, lung disease, connective tissue disease, and weight loss due to medication, anorexia, Addison's disease, dementia, depression, hypercalcemia, Parkinson's disease, and tuberculosis.
[0076] By adding the bacterial composition to antibiotic-free animal feed, it is possible to increase the body weight of animals consuming the animal feed to a level equal to or greater than that of animals consuming antibiotic-containing animal feed, and it is also possible to reduce pathogenic bacteria in the stomach to the same level as that of animals consuming typical antibiotic-containing animal feed. The bacterial composition can be used as an ingredient in animal feed without the need for the addition of antibiotics.
[0077] Furthermore, unlike conventional bacteria (Lactobacillus and Bifidobacteria) that are commercially available and cannot be easily incorporated into livestock production, the spore-form bacterial compositions of the present invention can be pelleted, sprayed, or easily mixed with animal feed and can also be added to drinking water.
[0078] Animal feed containing the bacterial composition can be fed to a wide variety of animal types and to animals of various ages, and can be fed periodically or at specific times (e.g., at birth, weaning, or when the animals are moved or transported).
[0079] The bacterial compositions can be used to promote weight gain and increase energy absorption in humans and non-humans (eg, food animals, including livestock).
[0080] The bacterial active ingredient of the bacterial composition can be produced using fermentation techniques well known in the art. In one embodiment, the active ingredient is produced using an anaerobic fermenter capable of supporting the rapid growth of a bacterial species belonging to the genus Clostridium. The anaerobic fermenter can be, for example, a stirred tank reactor or a disposable wave bioreactor. The growth of the bacterial species can be supported using media such as BL and EG media or similar types of media without animal components. The bacterial product can be purified and concentrated from the fermentation broth by conventional techniques such as centrifugation and filtration, and can optionally be dried and freeze-dried by techniques well known in the art.
[0081] The food and drink containing the bacterial composition described herein can be produced by a production technique well known in the art. One or more components (e.g., nutrients, etc.) that are effective in improving immune function through immunosuppressive action may be added to the food and drink. In addition, the food and drink may be made multifunctional by combining it with other components or other functional foods that exhibit functions other than improving immune function.
[0082] The bacterial composition can also be incorporated into foods that require processing steps that would destroy conventional probiotic strains. In particular, most commercially available probiotic strains cannot be incorporated into foods that require processing, for example, by heat treatment, long-term storage, freezing, mechanical stress, or high-pressure processing (e.g., extrusion and rolling). In contrast, the bacterial composition described herein has the advantageous property of forming spores, which allows it to be easily incorporated into such processed foods. For example, the bacterial composition in spore form can survive in dry foods and remain viable after ingestion. The bacterial composition can withstand pasteurization processing, typically performed at temperatures of about 70°C or higher to about 100°C or lower. The bacterial composition can be incorporated into dairy products that require a pasteurization step. Furthermore, the bacterial composition can withstand years of long-term storage, high-temperature processing such as baking and boiling, low-temperature processing such as freezing and refrigeration, and high-pressure processing such as extrusion and rolling.
[0083] There are many foods that require such harsh processing conditions, including foods that must be microwaved in order to be eaten (e.g., oatmeal), foods that must be baked in order to be eaten (e.g., muffins), foods that require short-term pasteurization and high-temperature processing in order to be eaten (e.g., milk), and foods that must be heated in order to be consumed (e.g., hot tea).
[0084] The amount of the bacterial composition to be administered or ingested can be empirically determined taking into consideration factors such as the age, weight, sex, symptoms, and health condition of the individual, and the type of bacterial composition to be administered or ingested (medicine, food, drink, etc.). For example, the dosage or intake per administration is generally 0.01 mg / kg body weight to 100 mg / kg body weight, and in a specific embodiment, 1 mg / kg body weight to 10 mg / kg body weight. Also described herein is a method for suppressing the immunity of a subject (reducing the immune response), which is characterized by administering or ingesting a bacterium belonging to the genus Clostridia or a physiologically active substance derived from the bacterium to the subject as described above.
[0085] The bacterial composition may be administered to an individual once or more than once. When the composition is administered more than once, it may be administered periodically (e.g., once a day, once every two days, once a week, once every two weeks, once a month, once every six months, or once a year), on demand, or irregularly. The appropriate frequency of administration (which may depend on the subject's host genetic factors, age, sex, and health or disease state, among other factors) may be empirically determined. For example, a patient may be administered a single dose of the composition, and the levels of each bacterial strain of the composition may be measured in fecal samples taken from the patient at various times (e.g., one day, two days, one week, two weeks, one month). A second dose may be administered when the level of bacteria has fallen, for example, to half of its maximum value, and so on.
[0086] A product (drug, food, beverage, or reagent) containing the bacterial composition or its instruction manual may include a document or description explaining that the product is used to suppress immunity (including a description that the product has an immunosuppressive effect and a description that the product has an effect of suppressing the proliferation or function of effector T cells). Here, "adding a warning to the product or its instruction manual" means adding a document or description to the product itself, container, packaging, etc., or adding a warning to printed matter such as an instruction manual, package insert, or promotional material that discloses information about the product.
[0087] <Method for inducing proliferation or accumulation of regulatory T cells> As described above and shown in the Examples, the proliferation or accumulation of regulatory T cells can be induced in an individual by administering the bacterial composition to the individual. There is thus provided a method for inducing proliferation or accumulation of regulatory T cells in an individual, the method comprising administering to the individual at least one substance selected from the group consisting of: (a) Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.(b) a culture supernatant of at least one (one, more than one) type of bacteria described / enumerated herein; (c) a bioactive substance derived from (one or more, at least one) type of bacteria described / enumerated herein; or a combination of any two or three of (a), (b) and (c). The individual is administered (provided) the bacterial composition in an amount sufficient to achieve the desired effect of inducing proliferation, accumulation or both proliferation and accumulation of regulatory T cells. The bacterial composition may be administered to an individual in need of treatment, reduction in severity of or prevention of at least one disease selected from autoimmune disease, inflammatory disease, allergic disease, and infectious disease.
[0088] It should be noted that an "individual" or "subject" may be healthy or diseased. The method may further comprise administering at least one antibiotic (one, one or more) before or in combination with the bacterial composition. The antibiotic administered may be an antibiotic that promotes recolonization of the digestive tract with gram-positive bacteria of the Clostridium genus, such as an antibiotic that reduces gram-negative bacteria. Examples of such antibiotics include aminoglycoside antibiotics (amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin and paromomycin), cephalosporin antibiotics (cefachlor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefoxotin), sulfonamides, ampicillin, and streptomycin.
[0089] In addition, prebiotic compositions that are not degraded in the upper digestive tract and promote the growth of enterobacteria in the intestinal tract, such as almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose (e.g., xyloglucan, alpha-glucan), amylopectin, and resistant starch, as well as growth factors such as acetyl-CoA, biotin, beet molasses, and yeast extract, selectively contribute to the growth of bacterial species in the composition belonging to the genus Clostridium. The method for inducing the proliferation and / or accumulation of regulatory T cells in an individual may include administering at least one substance selected from the above substances to the individual in combination with the bacterial composition. In addition, the present specification considers a composition that includes the bacterial composition and a prebiotic composition.
[0090] The antibiotic and the prebiotic composition or growth factor may be used in combination. Further, a therapeutic composition may be administered to an individual together with at least one substance selected from the group consisting of the bacterial composition, the antibiotic, and the prebiotic composition or growth factor.
[0091] Therapeutic compositions include, for example, one selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressants, cyclosporine A, mercaptopurine, azathioprine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, anti-leukotrienes, anticholinergic rhinitis drugs, anticholinergic decongestants, mast cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably those used in vaccinations with gradually increasing amounts of allergens), infliximab, adalimumab, certolizumab pegol, golimumab, or anti-TNF inhibitors such as etanercept, and combinations thereof. The therapeutic compositions provided herein may be administered prior to, in combination with, or after the bacterial composition, and may optionally be administered in combination with antibiotics, prebiotic compositions, growth factors, or any combination of antibiotics, prebiotic compositions, and growth factors.
[0092] There is no particular limitation on the combined use of the therapeutic composition with at least one substance selected from the group consisting of the bacterial composition, "antibiotics," and "prebiotic compositions or growth factors." For example, the "one substance" and the therapeutic composition are orally or parenterally administered to an individual simultaneously, or sequentially / individually as appropriate.
[0093] Whether administration of the bacterial composition induces proliferation and / or accumulation of regulatory T cells can be determined by increasing or enhancing at least one of the following indicators: the number of regulatory T cells, the proportion of regulatory T cells in the T cell population of the large intestine, the function of regulatory T cells, or the expression of a marker for regulatory T cells. A specific method is to measure the number or proportion of Foxp3-expressing Treg in a patient sample such as a biopsy or blood sample, the promotion (enhancement) of IL-10 expression, the promotion (enhancement) of CTLA4 expression, the promotion (enhancement) of IDO expression, the suppression of IL-4 expression, or colonization of an individual administered the bacterial composition as an indicator of the induction of an increase or accumulation of regulatory T cells.
[0094] Methods for detecting such expression include Northern blotting, RT-PCR, and dot blot for detecting gene expression at the transcriptional level; and ELISA, radioimmunoassay, immunoblotting, immunoprecipitation, and flow cytometry for detecting gene expression at the translational level.
[0095] Samples used to measure such indicators include tissues and body fluids taken from an individual, such as blood obtained by biopsy, and fecal samples.
[0096] Methods for predicting an individual's response to a bacterial composition by monitoring the individual's response to treatment with the composition In addition, Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium syndens, Clostridium saccharolyticum, Clostridium scin ... scindens), Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.The present invention describes a method for determining the amount (e.g., count) or proportion of at least one bacterial species selected from the group consisting of Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662. If the proportion or count of bacteria selected from the above list in an individual is lower than a baseline value obtained by performing a similar determination on a healthy individual (e.g., an individual who does not have / is not known to have a disease or condition that may be treated with the bacterial composition, such as an autoimmune disease, allergic condition, cancer, organ rejection, etc.), the individual is determined to be likely to respond to the bacterial composition. This determination can be used, for example, by a clinician to determine whether an individual or patient is likely to benefit from treatment with the bacterial composition or to select individuals or patients for inclusion in a clinical trial. The clinician can then administer the bacterial composition to the individual or patient in light of the determination that the individual or patient is likely to benefit from the treatment. This determination can also be used as a method to monitor the response of the individual to treatment with the described bacterial composition, where a higher measurement (relative to the measurement before treatment) after treatment with the bacterial composition indicates that the individual has responded well to the treatment (e.g., a positive indicator of successful colonization and enhanced immunosuppression in the individual). Optionally, the prediction and monitoring methods described herein can further include measuring the percentage or absolute number of other commensal species belonging to Clostridium clusters IV and XIVa in the individual's sample that are not present in the bacterial composition, where a lower value than the baseline value before treatment indicates a higher likelihood of a positive response to the treatment, and an increase in the value after treatment indicates that the individual has responded well to the treatment. The prediction and monitoring methods described herein can use various known methods to determine the composition of the microbiota. For example, 16S rRNA sequencing can be used.
[0097] <Methods of treating or preventing infectious or autoimmune diseases by using vaccine adjuvant compositions and vaccine compositions> As described above and shown in the Examples, the induction of Treg cells in the large intestine by bacteria belonging to the genus Clostridium plays an important role in local and systemic immune responses.The bacterial composition can also be used as an adjuvant to improve the efficacy of vaccine formulations.In one embodiment, the bacterial composition can be used as a vaccine adjuvant (e.g., as an adjuvant in a vaccination protocol that gradually increases the amount of allergen) to prevent or treat autoimmune or allergic diseases.
[0098] Examples of autoimmune diseases and allergic diseases include those described as "specific examples of target diseases" in <Composition having the effect of inducing the proliferation or accumulation of regulatory T cells>.
[0099] Other embodiments In addition, the bacterial composition can be administered to individuals undergoing antibiotic treatment. The inventors have shown that antibiotics acting on Gram+ bacteria, such as vancomycin or metronidazole, can effectively eliminate or significantly reduce bacterial species belonging to the genus Clostridia from the mammalian digestive tract, resulting in reduced levels of regulatory T cells (Example 5, Figure 30). Without wishing to be bound by theory, the important role of bacteria belonging to the genus Clostridia in maintaining immune tolerance strongly indicates that their absence or reduced levels may play an important role in autoimmune diseases characterized by impaired immune tolerance. Thus, individuals undergoing antibiotic treatment against Gram+ bacteria (e.g., individuals undergoing treatment for infections with pathogens such as C.difficile and Giardia) are at high risk of losing bacteria belonging to the genus Clostridia, leading to impaired immune tolerance, which can be "restored" by using the bacterial composition as a preventative measure. The bacterial composition can be administered either prior to, concurrently with, or after antibiotic treatment, preferably concurrently with or after antibiotic treatment. The bacterial composition is preferably administered in spore form to improve its resistance to residual antibiotics. Antibiotics against gram-positive bacteria include, but are not limited to, vancomycin, metronidazole, linezolid, ramoplanin, fidaxomicin, cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxotin, cefprozil, ceftobiprole); fluoroquinolone antibiotics (cipro, levaquin, floxin, tequin, avelox, norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, methicillin); and carbapenem antibiotics (ertapenem, doripenem, imipenem / cilastatin, meropenem).
[0100] <Method for selecting Treg-inducing organisms> In addition, a method for obtaining bacteria capable of inducing Tregs is described, the method comprising: (1) separating the spore-forming fraction of bacteria from fecal or biopsy samples obtained from a mammal, preferably a human (e.g., by chloroform treatment or heat treatment); (2) optionally, orally administering the spore-forming fraction to a non-human mammal, preferably a germ-free non-human mammal; (3) optionally, collecting a fecal sample from this non-human mammal and preparing a diluted fecal sample by diluting this fecal sample (e.g., 10-fold, 100-fold, 1,000-fold or 10,000-fold by volume), and orally administering this diluted sample to a second germ-free non-human mammal, where this optional step (3) may be repeated two or more times; (4) plating the spore-forming fraction obtained in (1) or the serial dilutions of the intestinal content samples of the non-human mammal of (3) under aerobic or obligately anaerobic conditions; and (5) selecting a single colony from this culture plate. This colony may be further evaluated for the ability of the bacteria to induce the proliferation and / or accumulation of regulatory T cells using known methods such as those described in the examples.
[0101] The following are examples for illustrative purposes of specific embodiments. These are in no way intended to be limiting.
[0102] Note that the mice used in the examples were prepared or produced as follows. In the following description, mice may be referred to as "SPF" or "GF". This "SPF" and "GF" indicate mice maintained in the absence of specific pathogens (SPF) and germ-free (GF), respectively.
[0103] <Mouse> C57BL / 6, Balb / c and IQI mice maintained under SPF or GF conditions were purchased from Sankyo Labo Services (Japan), SLC (Japan), Claire (Japan), or Jackson Laboratory (USA). GF and gnotobiotic mice were bred and maintained in the gnotobiotic facilities of the University of Tokyo, Yakult Central Institute, or Sankyo Labo Services. Myd88 - / - , Rip2 - / - and Card9 - / - Mice were generated as described in NPL1-3 and backcrossed to the C57BL / 6 genetic background for over eight generations. Foxp3 eGFP Mice were purchased from Jackson Laboratory.
[0104] < Il10 venus Mouse> In order to create a bicistronic region in which Il10 and Venus are encoded under the control of the Il10 promoter, a targeting construct was first created. Specifically, a cassette consisting of a neomycin resistance gene (neo), followed by an internal ribosome entry site (IRES), a yellow fluorescent protein (Venus), and an SV40 polyA signal (SV40 polyA) (IRES-Venus-SV40 polyA signal cassette, see Non-Patent Document 4) was inserted between the stop codon and the polyA signal (exon 5) of the Il10 gene. The resulting targeting construct was then used to cause homologous recombination with the Il10 gene region in the mouse genome. In this way, Il10 venus Allele-bearing Il10 venus Mice were generated (see FIG. 1). In FIG. 1, "tk" represents the gene encoding thymidine kinase, "neo" represents the neomycin resistance gene, and "BamH1" represents the cleavage site by the restriction enzyme BamH1.
[0105] Il10 venusGenomic DNA was extracted from the mice, treated with BamH1, and subjected to Southern blotting using the probes shown in Figure 1. The results are shown in Figure 2. Il10 venus The alleles of were detected as bands of 19 kb and 5.5 kb, respectively. Il10 venus Homologous recombination occurred in the mouse genome.
[0106] Furthermore, using FACSAria, Il10 venus CD4 in the lamina propria of mouse colon + Venus - Cells or CD4 + Venus + The cells were sorted. Then, real-time RT-PCR was performed using the ABI7300 system as described below to examine the expression level of IL-10 mRNA. + Venus + Since IL-10 mRNA expression was detected only in the cells, Il10 venus It was revealed that the expression of IL-10 mRNA in mice was accurately reflected as the expression of Venus. Il10 venus Pathogen-free conditions for mice were established at the Central Institute for Experimental Animals (Kawasaki, Japan). Il10 venus Mice were maintained in vinyl isolators from Sankyo Labo Services (Tokyo, Japan) and used in subsequent examples.
[0107] The experiments and analyses of the examples were carried out as follows.
[0108] <Methods for colonization of mice with mouse bacteria and their analysis> Mice colonized with SFB or Clostridium were generated as described in NPL5,6. The cecal contents or feces of the obtained gnotobiotic mice were dissolved in sterile water or anaerobic diluent. The dissolved cecal contents or feces were orally administered to GF mice either directly or after treatment with chloroform. Three strains of Lactobacillus spp. and 16 strains of Bacteroides spp. were separately cultured anaerobically on BL and EG agar media. The cultured bacteria were collected, suspended in anaerobic TS medium, and orally administered to GF mice. The status of bacterial colonization in mice was evaluated by microscopic observation of smears of fecal pellets.
[0109] <Isolation of intestinal lamina propria lymphocytes and flow cytometry> The small and large intestines were harvested and cut longitudinally. The cecum was also isolated and the cecal contents were either frozen directly at -80°C or suspended in 2 ml of PBS followed by the addition of 40% glycerol (final concentration 20%), flash frozen in liquid nitrogen and stored at -80°C until use. The large and small intestines were washed with PBS to remove all luminal contents and shaken at 37°C for 20 min in Hanks' balanced salt solution (HBSS) containing 5 mM EDTA. After removing the epithelial cells, muscle layer and adipose tissue with forceps, the lamina propria was minced into small pieces and incubated in a shaking water bath with RPMI 1640 containing 4% fetal bovine serum, 1 mg / ml collagenase D, 0.5 mg / ml dispase and 40 μg / ml DNase I (all from Roche Diagnostics) for 1 h at 37°C. The digested tissue was washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (GE Healthcare) and layered on 2.5 ml of 80% Percoll in a 15 ml Falcon tube. Percoll gradient separation was performed by centrifugation at 800 g for 20 min at 25°C. Lamina propria lymphocytes were collected from the interface of the Percoll gradient and suspended in ice-cold PBS. For analysis of regulatory T cells, isolated lymphocytes were labeled with LIVE / DEAD fixable violet dead cell staining kit (Invitrogen) to exclude dead cells for analysis. Cells were washed with staining buffer containing PBS, 2% FBS, 2 mM EDTA and 0.09% NaN3 and surface CD4 was stained with PECy7-labeled anti-CD4 antibody (RM4-5, BD Biosciences). Intracellular staining of Foxp3 and Helios was performed using Alexa700-conjugated anti-Foxp3 antibody (FJK-16s, eBioscience), Alexa647-conjugated anti-Helios (22F6, eBioscience) and Foxp3 Staining Buffer Set (eBioscience). For analysis of Th1 and Th17 cells, isolated lymphocytes were stimulated with 50 ng / ml phorbol 12-myristate 13-acetate (PMA, Sigma) and 1 μg / ml ionomycin (Sigma) in the presence of GolgiStop (BD Biosciences) for 4 h.After 4 h of incubation, cells were washed with PBS, labeled with LIVE / DEAD fixable violet dead cell staining kit, and stained for surface CD4 with PECy7-conjugated anti-CD4 antibody. Cells were washed, fixed with Cytofix / Cytoperm, permeabilized with Perm / Wash buffer (BD Biosciences), and stained with APC-conjugated anti-IL-17 antibody (eBio17B7, eBioscience) and FITC-conjugated anti-IFN-γ antibody (XMG1.2, BD Biosciences). Antibody-stained cells were analyzed on an LSR Fortessa (BD Biosciences), and data were analyzed using Flow Jo software (Treestar).
[0110] <Real-time RT-PCR> cDNA was synthesized from RNA prepared using the RNeasy Mini Kit (Qiagen) using MMV reverse transcriptase (Promega). The obtained cDNA was analyzed by real-time RT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) and the ABI 7300 real time PCR system (Applied Biosystems) or by real-time RT-PCR using SYBR Premix Ex Taq (TAKARA) and the LightCycler 480. The values obtained for each sample were normalized by the amount of GAPDH. Primer sets were designed using Primer Express Version 3.0 (Applied Biosystems), and those that showed 90% or more sequence identity in the initial evaluation were selected. The primer sets used were as follows: Foxp3 5'-GGCAATAGTTCCTTCCCAGAGTT-3' (SEQ ID NO: 1) 5'-GGGTCGCATATTGTGGTACTTG-3' (SEQ ID NO: 2) CTLA4 5'-CCTTTTGTAGCCCTGCTCACTCT-3' (SEQ ID NO: 3) 5'-GGGTTCACCTGTATGGCTTCAG-3' (SEQ ID NO: 4) GITR 5'-TCAGTGCAAGATCTGCAAGCA-3' (SEQ ID NO:5) 5'-ACACCGGAAGCCAAACACA-3' (SEQ ID NO: 6) IL-10 5'-GATTTTAATAAGCTCCAAGACCAAGGT-3' (SEQ ID NO: 7) 5'-CTTCTATGCAGTTGATGAAGATGTCAA-3' (SEQ ID NO: 8) GAPDH 5'-CCTCGTCCCGTAGACAAAATG-3' (SEQ ID NO: 9) 5'-TCTCCACTTTGCCACTGCAA-3' (SEQ ID NO: 10) Mmp2 5'-GGACATTGTCTTTGATGGCA-3' (SEQ ID NO: 11) 5'-CTTGTCACGTGGTGTCACTG-3' (SEQ ID NO: 12) Mmp9 5'-TCTCTGGACGTCAAATGTGG-3' (SEQ ID NO: 13) 5'-GCTGAACAGCAGAGCCTTC-3' (SEQ ID NO: 14) Mmp13 5'-AGGTCTGGATCACTCCAAGG-3' (SEQ ID NO: 15) 5'-TCGCCTGGACCATAAAGAA-3' (SEQ ID NO: 16) Ido1 5'-AGAGGATGCGTGACTTTGTG-3' (SEQ ID NO: 17) 5'-ATACAGCAGACCTTCTGGCA-3' (sequence number 18).
[0111] <Preparation and culture of colonic intestinal epithelial cells (IEC)> First, the colon was harvested, cut longitudinally, and rinsed with PBS. The colon was then treated with 1 mM dithiothreitol (DTT) for 30 min at 37°C on a shaker, followed by vortexing for 1 min to disrupt epithelial integrity. Dissociated intestinal epithelial cells (IECs) were collected, suspended in 5 ml of 20% Percoll, and layered onto 2.5 ml of 80% Percoll in a 15 ml Falcon tube. The tube was then centrifuged at 780g at 25°C for 20 min to perform cell separation by Percoll density gradient centrifugation. Cells at the interface were collected and used as colonic IECs (purity ≥90%, viability ≥95%). The collected IECs were suspended in RPMI containing 10% FBS and diluted to 1 × 10 5 IECs were cultured in 24-well plates for 24 hours, after which the culture supernatants were harvested and the levels of active TGF-β1 were measured by ELISA (Promega).
[0112] For in vitro T cell culture, MACS-purified splenic CD4 + T cells were grown in a 96-well round-bottom plate at 1.5 x 10 cells per well. 5 IECs were cultured in 50% oxidized medium containing IECs isolated from GF mice or Clostridium-colonized mice, with 25 ng / ml hIL-2 (Peprotech) in the presence or absence of 25 μg / ml anti-TGF-β antibody (R&D). Anti-CD3 and anti-CD28 antibodies (BD Bioscience) were bound to the round-bottom plate at 10 μg / ml. After 5 days of culture, CD4 + T cells were harvested and subjected to real-time PCR.
[0113] <Experimental colitis model> C57BL / 6 mice (2 weeks old) were orally administered a fecal suspension from Clostridium-colonized mice and were housed in a normal environment for 6 weeks.
[0114] To prepare a DSS-induced colitis model, mice were given 2% (wt / vol) DSS (reagent grade, DSS salt, molecular weight = 36-50 kD, MP Biomedicals) in drinking water for 6 days.
[0115] To prepare an oxazolone-induced colitis model, mice were pre-sensitized by percutaneous application of 150 μl of a 3% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma-Aldrich) / 100% ethanol solution. Five days later, 150 μl of a 1% oxazolone / 50% ethanol solution was re-administered into the rectum of the pre-sensitized mice under light anesthesia. The rectal administration was performed using a 3.5F catheter.
[0116] The body weight, occult blood, visible bleeding, and stool hardness of each mouse were analyzed daily. Furthermore, according to the description of "S. Wirtz, C. Neufert, B. Weigmann, M. F. Neurath, Nat Protoc 2, 541 (2007)", the weight loss rate, intestinal bleeding (no bleeding, occult blood (hemoccult+), or visible bleeding), and stool hardness (normal stool, soft stool, or diarrhea) were numerically evaluated, and the disease activity index (DAI) was calculated.
[0117] <OVA-specific IgE response> Fecal suspensions of Clostridium-colonized mice (2 weeks old) were inoculated into BALB / c SPF mice and the mice were housed in a conventional environment. Then, 1 μg of OVA (Grade V, Sigma) and 2 mg of alum (Thermo Scientific) in a total volume of 0.2 ml were injected intraperitoneally into the mice (at 4 and 6 weeks of age). Serum was collected weekly from the base of the tail of these mice, and OVA-specific IgE was measured by ELISA (Chondrex). Then, splenocytes were collected at 8 weeks of age, seeded at 1×10 6 cells per well in a 96-well plate, and stimulated with OVA (100 μg / ml) for 3 days. Thereafter, the culture supernatant was collected, and the IL-4 and IL-10 levels were measured by ELISA (R&D).
[0118] <Statistical analysis> The differences between the control group and the experimental group were evaluated by Student's t-test.
[0119] <Chloroform treatment and oral inoculation of fecal samples into GF mice> Human feces (2 g) from a healthy subject (Japanese, male, 29 years old) were suspended in 20 ml of phosphate-buffered saline (PBS), passed through a 70-μm cell strainer, and aggregates and residues were removed. Then, the fecal suspension was mixed with or without the addition of chloroform (final concentration 3%) and incubated in a shaking water bath for 60 minutes. The fecal suspension without chloroform treatment was orally inoculated into germ-free (GF) mice (250 μl / mouse). After evaporating chloroform by aerating N2 gas for 30 minutes, an aliquot containing the chloroform-resistant (spore-forming) fraction of human intestinal bacteria was inoculated into IQI GF mice. Each ex-GF mouse group was separately housed in a vinyl isolator for 3 weeks or 4 weeks.
[0120] <Cohabitation experiment> To evaluate whether Treg-inducing human bacteria can be horizontally transmitted, IQI GF mice were co-housed in a vinyl isolator for 4 weeks with ex-GF mice (the mice of Example 21) colonized with chloroform-treated human feces (designated as 6 individuals: mice #D1 to #D6).
[0121] <Inoculation of diluted cecal contents into GF mice> The frozen cecal contents of ex-GF mice (#C4) inoculated with chloroform-treated human feces were suspended in 10-fold volume (w / v) of PBS, passed through a 70-μm cell strainer, and treated with 3% chloroform. Then, the suspension was diluted 2000-fold (4 individuals designated as mice #E1 to #E4) or 20000-fold (8 individuals designated as mice #F1 to #F8) with PBS and orally inoculated into GF IQI mice (2.5×10 5 cells or 2.5×10 4 cells / 250 μl / mouse). Four weeks later, lymphocytes were recovered from the large and small intestines, and the proportion of Foxp3 + Treg cells and their Helios expression were analyzed. The cecal contents were frozen and stored at -80 °C until use.
[0122] <Re-colonization experiment> Frozen cecal contents of ex-GF mice (#F3, 7 and 8) inoculated with 20000-fold dilution were suspended in 10-fold volume (w / v) of PBS, passed through a 70 μm cell strainer and treated with 3% chloroform. The suspension was orally inoculated into GF IQI mice (five, four or four mice, designated mice #G1-#G5, #H1-#H4 or #I1-#I4, respectively). After 4 weeks, the large and small intestines were harvested and analyzed for Foxp3 + The percentage of Treg cells and their Helios expression were analyzed. Cecal contents were suspended in 20% glycerol solution, flash frozen in liquid nitrogen, and stored at -80°C.
[0123] <Establishment experiment of cultured bacteria> A glycerol stock of cecal contents from #G2 mice was diluted with PBS and plated on a BL agar plate. After 48 hours, the plate was scraped with a plate scraper to recover all bacterial colonies, which were then inoculated into GF IQI mice (four mice named #K1 to #K4). Using the BL agar plate, six strains were isolated from a frozen stock of cecal contents from #F8 mice. These isolated strains were then inoculated into GF IQI mice (four mice named #J1 to #J4). (Details of the culture method will be described later.)
[0124] <Quantitative PCR analysis of 16S rRNA gene> Bacterial genomic DNA was isolated from human feces of the above-mentioned healthy subjects (human feces), cecal contents of GF mice gavaged with chloroform-treated human feces (cecal contents of B-4 mice), or feces of SPF ICR mice (feces of SPF mice) using the QIAamp DNA Stool mini kit (QIAGEN). The isolated DNA was used as a template for quantitative PCR. The amplification program consisted of one cycle at 95°C for 1 min, followed by 50 cycles at 95°C for 10 s and 60°C for 30 s. Quantitative PCR analysis was performed using a LightCycler480 (Roche). Relative amounts were calculated by the ΔCt method and normalized to the total bacterial amount. The following primer sets were used: total bacteria, 5'-GGTGAATACGTTCCCGG-3' (SEQ ID NO: 45) and 5'-TACGGCTACCTTGTTACGACTT-3' (SEQ ID NO: 46); Clostridium cluster XIVa (Clostridium coccoides subgroup), 5'-AAATGACGGTACCTGACTAA-3' (SEQ ID NO: 47) and 5'-CTTTGAGTTTCATTCTTGCGAA-3' (SEQ ID NO: 48); Clostridium cluster IV (Clostridium leptum leptum), 5'-CCTTCCGTGCCGSAGTTA-3' (SEQ ID NO: 49) and 5'-GAATTAAACCACATACTCCACTGCTT-3' (SEQ ID NO: 50); Bacteroides, 5'-GAGAGGAAGGTCCCCCAC-3' (SEQ ID NO: 51) and 5'-CGCTACTTGGCTGGTTCAG-3' (SEQ ID NO: 52); Bifidobacterium, 5'-CGGGTGAGTAATGCGTGACC-3' (SEQ ID NO: 53) and 5'-TGATAGGACGCGACCCCA-3' (SEQ ID NO: 54). Note that mice gavaged with chloroform-treated human feces had higher levels of spore-forming bacteria, such as Clostridium cluster XIVa and IV, and significantly reduced non-spore-forming bacteria, such as Bacteroides and Bifidobacterium, compared to pre-chloroform-treated human feces.
[0125] Isolation of DNA from cecal contents for 16S rRNA gene metasequencing The cecal contents of A1-1, A2-4, B-4, E-3, E-7, E-8, F-2, G-3, H-3, I-3 and J-3 were collected by centrifugation at 5000×g for 10 min at 4°C and suspended in 10 ml of Tris-EDTA containing 10 mM Tris-HCl and 1 mM EDTA (pH 8) before being used for DNA isolation. Lysozyme (SIGMA, 15 mg / ml) was added to the cell suspension. After incubation at 37°C for 1 h with gentle agitation, purified achromopeptidase (Wako) was added (2000 units / ml final) and incubated at 37°C for 30 min. Sodium dodecyl sulfate (1% final) was then added to the cell suspension and mixed well. Proteinase K (Merck) was then added to the suspension (1 mg / ml final) and the mixture was incubated at 55°C for 1 h. High molecular weight DNA was isolated and purified by phenol / chloroform extraction, ethanol, and finally polyethylene glycol precipitation.
[0126] <Meta sequence of 16S rRNA gene> An aliquot of this DNA was used for PCR amplification and sequencing of the bacterial 16S rRNA gene. (i) Modified primer 8F (5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG+barcode+agrgtttgatymtggctcag-3' (SEQ ID NO: 55)) consisting of the 454 adapter sequence (underlined) and a sample-specific error correction barcode (10 bases, bold) and the universal bacterial primer 8F; (ii) A modified primer 338R (5'-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG+tgctgcctcccgtaggagt-3' (SEQ ID NO: 56)) containing the 454 adapter sequence (underlined) and bacterial primer 338R was used to generate an approximately 330 bp amplicon spanning variable regions 1-2 (V1-2) of the gene. Polymerase chain reactions were performed on each fecal DNA sample. Each 50 μL reaction contained 40 ng of DNA, 5 μl of 10x Ex Taq buffer (TAKARA), 5 μl of 2.5 mM dNTP mix, 0.2 μl of Ex Taq and 0.2 μM of each primer. PCR conditions consisted of an initial denaturation step performed at 96 °C for 2 min, followed by 20 cycles of denaturation (96 °C, 30 s), annealing (55 °C, 45 s) and amplification (72 °C, 1 min), and finally an amplification step performed at 72 °C for 10 min. Amplicons generated from each sample were then purified using AMPur XP (Beckman Coulter). DNA amount was quantified using Quant-iT Picogreen dsDNA Assay Kit (Invitrogen) and TBS-380mini fluorometer (Turner Biosystems). Amplified DNA was used as template for 454GS Junior (Roche) pyrosequencing. Sequencing was performed using GS Junior Titanium emPCR Kit-Lib-L, GS Junior Titanium Sequencing Kit and GS Junior Titanium PicoTiterPlate Kit (all from Roche) according to the manufacturer's instructions (GS Junior Titanium Series, emPCR Amplification Method Manual-Lib-L and Sequencing Method Manual). The resulting sequences (3400 reads were obtained for each sample) were grouped into OTUs based on sequence similarity (>97% identity). Representative sequences from each OTU were compared to sequences in a nucleic acid database (Ribosomal Database Project) using BLAST to determine closest relatives. The OTUs were then grouped into species based on their closest relatives. All data and read numbers for the closely related species are shown in Table 1.
[0127] <Isolation of Bacterial Strains> Isolation of bacterial strains from the cecal contents of #F8, #G2, #I1, and #K3 was performed by plating serial dilutions of cecal samples on BL agar plates (Eiken Chemical) or EG agar plates under aerobic or strictly anaerobic conditions (80% N2, 10% H2, 10% CO2). EG agar plates contained medium with the following components (expressed per liter): meat extract 500 ml; Proteose peptone No. 3 (10.0 g, Difco); yeast extract (5.0 g, Difco); Na2HPO4 (4.0 g); D(+)-glucose (1.5 g); soluble starch (0.5 g); L-cystine (0.2 g), L-cysteine-HCl-H2O (0.5 g); Tween 80 (0.5 g); Bacto Agar (16.0 g, Difco); defibrinated horse blood (50 ml). After 2 or 4 days of incubation at 37°C, single colonies were picked and cultured in ABCM broth or on EG agar plates at 37°C for another 2 or 4 days, respectively. The isolated strains were recovered in EG stock medium (10% DMSO) and stored at -80°C. To reinoculate mice with the suspension of the isolated strains, TS medium (trypticase soy broth w / o dextrose 27.5 g, Na2CO3 0.84 g, L-cysteine-HCl-H2O 0.5 g, distilled water 1000 ml, pH adjusted to 7.2 ± 0.2 with NaOH, then autoclaved at 115 °C for 15 min) was used. To identify the isolated strains, sequencing of the gene encoding 16S rRNA was performed. The 16S rRNA gene was amplified by colony PCR using KOD FX (TOYOBO).The 16S rRNA gene specific primer pair used was: 8F (5'-AGAGTTTGATCMTGGCTCAG-3' (SEQ ID NO: 57)) and primers for C. indolis, C. bolteae, Bacteroides sp. MANG, L. coli DJF_VP30, A. colihominis, Ruminococcus sp. sp. ID8, C. lavalense, C. symbiosum and E. contortum or 1513R (5'-ACGGCTACCTTGTTACGACTT-3' (SEQ ID NO: 59)) for C. saccharogumia, C. ramosum, F. plautii, C. hathewayi, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf Clostridium sp. MLG055, using GeneAmp PCR Amplification was performed using a System 9700 (Applied Biosystems). The amplification program consisted of one cycle of 98°C for 2 min, followed by 40 cycles of 98°C for 10 s, 57°C for 30 s, and 68°C for 40 s. Each amplified DNA was purified from the reaction mixture using an Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare). Sequence analysis was performed using a BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) and an Applied Biosystems 3730xl DNA analyzer (Applied Biosystems). The obtained sequences were compared with sequences in a nucleic acid database using BLAST to determine closest relatives.The closest relatives and % identity of all isolates, genus-species information of the closest relatives, Clostridium cluster, mouse ID of origin, maximum similarity and culture medium of the isolates are summarized in Table 2.
[0128] Example 1 First, we investigated whether the accumulation of regulatory T cells (Treg cells) in the lamina propria of the colonic mucosa is dependent on commensal bacteria. Specifically, lymphocytes were isolated from the peripheral lymph nodes (pLNs) of Balb / c mice raised in the absence of specific pathogens (SPF) or from the lamina propria of the colon or small intestine (SI) of the mice. CD4 and Foxp3 were stained with antibodies. CD4 + Foxp3 in lymphocytes + The proportion of cells expressing Foxp3 was analyzed by flow cytometry. The results showed that the lamina propria of the digestive tract, especially the colonic lamina propria, of mice maintained in a specific pathogen-free (SPF) environment was rich in Foxp3 + It was revealed that Treg cells are present at a high frequency. Furthermore, Foxp3 + The number of Treg cells gradually increases until 3 months of age, but Foxp3 in peripheral lymph nodes is not increased. + We found that the number of Treg cells remained essentially constant from 2 weeks after birth.
[0129] Example 2 Next, we investigated whether the accumulation of Treg cells over time in the large intestine revealed in Example 1 is related to colonization of intestinal symbiotic bacteria. Specifically, we analyzed the expression of CD4 and Foxp3 in lymphocytes isolated from the small intestine, large intestine, and peripheral lymph nodes of mice (8-week-old: Balb / c mice, IQI mice, and C57BL / 6 mice) kept in a germ-free (GF) or SPF environment. Almost the same results were obtained in more than three independent experiments.
[0130] We also collected lamina propria lymphocytes from SPF and GF mice (Balb / C or C57BL / 6 mice). CD4 and Foxp3 were stained with antibodies. The lamina propria lymphocytes were then analyzed by FACS.
[0131] In addition, lymphocytes were isolated from the lamina propria of the large intestine, lamina propria of the small intestine (SI), Peyer's patches (PP), and mesenteric lymph nodes (MLN) of mice (SPF C57BL / 6 mice) that had been orally administered antibiotics with water for 8 weeks. CD4 and Foxp3 were stained with antibodies. Lymphocytes were then analyzed by FACS. Similar results were obtained in more than two independent experiments (CD4 + Foxp3 in cells + The following antibiotics were used in combination as described in the following literature: Ampicillin (A; 500 mg / L, Sigma) Vancomycin (V; 500mg / L, NACALAI TESQUE, INC) Metronidazole (M; 1g / L, NACALAI TESQUE, INC) Neomycin (N; 1g / L, NACALAI TESQUE, INC.) Rakoff-Nahoum, J.Paglino, F.Eslami-Varzaneh, S.Edberg, R.Medzhitov, Cell 118,229(Jul 23, 2004) Fagarasan et al., Science 298, 1424 (Nov 15, 2002).
[0132] The results show that Foxp3 expression in the small intestine or peripheral lymph nodes of GF mice + CD4 + The frequency and absolute number of Treg cells were equal to or greater than those in SPF mice. The numbers of Treg cells in the small intestinal lamina propria, Peyer's patches, and mesenteric lymph nodes of SPF mice orally administered antibiotics for 8 weeks were equal to or greater than those in SPF mice not administered the antibody. On the other hand, the number of Foxp3 Treg cells in the colonic lamina propria of GF mice was 100%. + CD4 +The number of Treg cells in the colonic lamina propria of SPF mice was significantly decreased compared to that in SPF mice. This decrease was observed in mice of different genetic backgrounds (Balb / c, IQI, C57BL / 6) and in mice housed in different animal facilities. We also found that the number of Treg cells in the colonic lamina propria of SPF C57BL / 6 mice administered antibiotics was significantly decreased.
[0133] Example 3 Next, we directly confirmed whether the decrease in the number of Treg cells in the colonic mucosa lamina propria of GF mice shown in Example 2 was due to the absence of microbiota. Specifically, fecal suspensions of B6 SPF mice purchased from Jackson Laboratory were orally administered to GF-IQI mice (conventionalized). Three weeks after administration, lymphocytes were isolated from the colonic mucosa lamina propria and CD4 + The expression of Foxp3 in lymphocytes was analyzed. The results showed that the number of Treg cells in the lamina propria of the small intestine did not change. However, the number of Treg cells in the lamina propria of the large intestine increased significantly. Therefore, the expression of Foxp3 in the lamina propria of the large intestine + While host-microbe interactions play an important role in the accumulation of Treg cells, it has become clear that there is a different mechanism for the accumulation of Treg cells in the small intestinal lamina propria.
[0134] Example 4 Next, Foxp3 expression in mouse gut-associated lymphoid tissue and the colonic lamina propria was analyzed according to the method described in MNKweon et al., J Immunol 174, 4365 (Apr 1, 2005). +We investigated the relationship between the number of CD4+ cells in the lamina propria of the colonic mucosa of LTβR-Ig-treated mice and that of rat IgG1-treated mice. Specifically, 100 μg of an extracellular domain recombinant protein (a fusion protein of lymphotoxin β receptor (LTβR) and the Fc portion of human IgG1 (LTβR-Ig), see Honda et al., J Exp Med 193, 621 (Mar 5, 2001)) was intraperitoneally injected into C57BL / 6 mice on day 14 of pregnancy. LTβR-Ig was also intraperitoneally injected into fetuses obtained from these mice, and mice in which isolated lymphoid follicles (ILFs), Peyer's patches (PPs), and colonic patches (CPs) were completely removed were generated. The CD4+ cells in the lamina propria of the colonic mucosa of LTβR-Ig-treated mice and that of rat IgG-treated mice (controls) were then analyzed. + Foxp3 in cells + The percentage of cells was analyzed by FACS. The results showed that the lamina propria of the colonic mucosa of mice lacking isolated lymphoid follicles, Peyer's patches, and colonic patches (LTβR-Ig-treated mice) expressed Foxp3 + Thus, the decrease in the number of Treg cells in the colonic lamina propria of GF mice and antibiotic-treated mice was not simply due to a secondary effect of hypoplasia of the gut-associated lymphoid tissue, but was due to a failure to transduce specific signals induced by gut bacteria that promote Treg cell accumulation in the colonic lamina propria.
[0135] Example 5 To investigate whether a specific intestinal flora induces the accumulation of colonic Treg cells, we administered vancomycin, an antibiotic against gram-positive bacteria, or polymyxin B, an antibiotic against gram-negative bacteria, to SPF mice (4 weeks of age or older) for 4 weeks and increased the number of CD4 + Foxp3 in cell populations + Percentage of cells (CD4 [%] Foxp3 +) were analyzed. The results showed that the number of Treg cells in the colon of mice treated with vancomycin was significantly reduced compared to controls. In contrast, the number of Treg cells in mice treated with polymyxin B was not affected. These findings suggest that gram-positive commensal bacteria play a major role in the accumulation of Treg cells.
[0136] Example 6 Recent reports suggest that spore-forming bacteria play an important role in intestinal T cell responses (see V. Gaboriau-Routhiau et al., Immunity 31, 677 (Oct 16, 2009)). Therefore, fecal microorganisms (spore-forming bacterial fraction) resistant to 3% chloroform were orally administered to GF mice, and then CD4 + Foxp3 in cell populations + Percentage of cells (CD4 [%] Foxp3 + ) was analyzed.
[0137] Three weeks after administration of chloroform-treated feces, the number of Treg cells in the treated mice had increased significantly to the same level as that in SPF mice and GF mice force-fed with untreated feces.
[0138] Therefore, taking into consideration the results shown in Example 5, it is highly likely that certain constituent bacteria of the resident microbiota belong to the Gram-positive group, and it has become clear that the spore-forming fraction plays an important role in inducing Treg cells.
[0139] Example 7 Next, the species of intestinal bacteria that induces the accumulation of colonic Treg cells suggested in Examples 4 to 6 were identified. Specifically, GF-Balb / c mice or GF-IQI mice were fed segmented filamentous bacteria (SFB), 16 strains of Bacteroides (Bactero. (6 strains of B. vulgatus, 7 strains of B. acidifaciens group 1, and 3 strains of B. acidifaciens group 2)), 3 strains of Lactobacillus (Lacto. (L. acidophilus, L. fermentum, and L. murinum)), and 46 strains of Clostridium (Clostridium). Itoh, K. and Mitsuoka, T. Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice. Lab. Animals 19:111-118 (1985)) or microbiota collected from mice raised under conventional conditions (SPF). Mice were maintained in vinyl isolators for 3 weeks. CD4 cells were then isolated from the large and small intestines of the mice. The number of Treg cells in the large and small intestines was analyzed by flow cytometry.
[0140] Bacteria belonging to the genus Clostridium were classified by determining the 16S rRNA sequence as follows. Specifically, the bacterial 16S rRNA gene was sequenced using a 16S rRNA gene-specific primer pair: The fragments were amplified by PCR using 5'AGAGTTTGATCMTGGCTCAG-3' (SEQ ID NO: 60) and 5'ATTACCGCGGCKGCTG-3' (SEQ ID NO: 61) (see T. Aebischer et al., Vaccination prevents Helicobacter pylori-induced alterations of the gastric flora in mice. FEMS Immunol. Med. Microbiol. 46, 221-229 (2006)). The 1.5 kb PCR product was then inserted into the pCR-Blunt vector. The inserts were sequenced and compared using the ClustalW software program. The resulting 16S rRNA gene sequences from strains 1 to 41 of the 46 strains of Clostridium bacteria are shown in SEQ ID NOs: 21 to 61. A phylogenetic tree was constructed by the neighbor-joining method using Mega software based on the sequences of the 41 Clostridium strains and known bacterial sequences obtained from the Genbank database.
[0141] The results showed that colonization of GF mice with segmented filamentous bacteria (SFB) had no effect on the number of Treg cells in the colon. Similar results were obtained in mice colonized with a cocktail of three strains of Lactobacillus. On the other hand, mice colonized with 46 strains of Clostridium bacteria showed a significant increase in Foxp3 in the lamina propria of the colonic mucosa. + It was found that colonization of the small intestine with 16 strains of Bacteroides also significantly increased the number of Treg cells in the large intestine. However, the degree of increase varied depending on the genetic background of the mice. Importantly, this accumulation was promoted regardless of the genetic background of the mice, and even when colonized with only one bacterial genus, the number of Treg cells in the small intestine was increased to a level similar to that in SPF mice. It was also found that colonization with Clostridium did not change the number of Treg cells in the lamina propria of the small intestine. It is noteworthy that colonization with 16 strains of Bacteroides also significantly increased the number of Treg cells in the large intestine. However, the degree of increase varied depending on the genetic background of the mice.
[0142] Example 8 Next, we analyzed the expression of CD4, Foxp3, and Helios in thymic and colonic LP lymphocytes of SPF mice, GF mice, Lactobacillus-colonized mice, and Clostridium-colonized mice by flow cytometry. The results showed that Foxp3 expression in SPF mice and Clostridium-colonized mice was significantly higher than that in GF mice. + Most of the cells did not express Helios. Note that Helios is a transcription factor known to be expressed in thymus-derived natural Treg cells (see AMThornton et al., J Immunol 184, 3433 (Apr 1, 2010)). Therefore, it was suggested that most of the Treg cells observed in SPF mice and Clostridium-colonized mice were Treg cells induced in the periphery (so-called iTreg cells).
[0143] Example 9 We next examined whether colonization with Clostridium or other bacteria affects other T cells. Specifically, GF IQI mice were colonized with SFB, 16 strains of Bacteroides, 46 strains of Clostridium, or microbiota collected from mice raised under conventional conditions (SPF). After 3 weeks, lymphocytes from the colonic lamina propria were isolated from these mice and stimulated with PMA (50 ng / ml) and ionomycin (1 μg / ml) for 4 hours in the presence of Golgistop (BD Bioscience). After stimulation, intracellular cytokines were stained using anti-IL-17 PE antibody (TC11-18H10) and anti-IFN-g FITC antibody (BD Bioscience) according to the instructions of the cytofix / cytoperm kit (BD Bioscience). CD4 + IFN-γ in leukocytes + Cells or IL-17 + The percentage of colonized Th1 cells (CD4 + IFN-γ + cells), but had no effect on Th17 cells (CD4 + IL-17+ These results suggest that Clostridium is a bacterial genus that specifically induces Treg cells.
[0144] Example 10 46 strains of Clostridium typhimurium were identified as CD8 + It has been reported that Clostridium truncatula affects the accumulation of intestinal intraepithelial lymphocytes (IEL). Therefore, Clostridium truncatula regulates various aspects of the immune system, and as mentioned above, it is thought to exert a remarkable ability in the induction and maintenance of Treg cells, especially in the large intestine. In addition, it is known that transforming growth factor-β (TGF-β), a type of cytokine, plays an important role in regulating the development of Treg cells.
[0145] We therefore investigated whether colonization with Clostridium leads to a TGF-β-rich colonic environment.Specifically, we first cultured the whole colons of GF mice, Clostridium-colonized mice, and Lactobacillus-colonized mice for 24 hours, and then measured the active TGF-β (TGF-β1) concentration in the culture supernatant by ELISA (four mice per group were analyzed).
[0146] The results show that TGF-β was produced at significantly higher levels in the colons of Clostridium-colonized mice than in the colons of GF mice and Lactobacillus-colonized mice.
[0147] Next, intestinal epithelial cells (IEC) from GF mice and Clostridium-colonized mice were cultured for 24 hours, and the concentration of active TGF-β (TGF-β1) in the culture supernatant was measured by ELISA (four mice per group were analyzed).
[0148] The results show that TGF-β was detected in the culture supernatants of IECs isolated from Clostridium-colonized mice, but not in the culture supernatants of IECs isolated from GF mice.
[0149] Next, as mentioned above, splenic CD4 +T cells were cultured for 5 days in the presence or absence of anti-TGF-β antibodies with 50% oxidized medium containing IECs isolated from GF mice or Clostridium-colonized mice and anti-CD3 antibodies, then T cells were harvested and analyzed for Foxp3 expression by real-time RT-PCR.
[0150] The results showed that the culture supernatant of IEC from Clostridium-colonized mice was used to treat splenic CD4 + Addition of this compound to T cells promoted their differentiation into Foxp3-expressing cells, whereas the differentiation into Treg cells was inhibited by anti-TGF-β antibody.
[0151] We examined the expression of MMP2, MMP9, and MMP13, which are thought to contribute to the activation of latent TGF-β. We also examined the expression of indoleamine 2,3-dioxygenase (IDO), which is thought to be involved in the induction of Treg cells. Specifically, germ-free C57BL / 6 mice were orally administered 46 strains of Clostridium spp. (Clost.) or 3 strains of Lactobacillus spp. (Lacto.) after 3 weeks of administration, and IECs were collected and the relative mRNA expression levels of MMP2, MMP9, MMP13, and IDO genes were analyzed by real-time RT-PCR (three mice per group were analyzed).
[0152] For the relationship between activation of latent TGF-β and the above-mentioned MMPs, see D'Angelo et al., J. Biol. Chem. 276, 11347-11353, 2001;Heidinger et al., Biol. Chem. 387, 69-78, 2006;Yu et al., Genes Dev. i4, 163-176, 2000. For the relationship between IDO and Treg cell induction, see G. Matteoli et al., Gut 59, 595 (May, 2010).
[0153] The results show that, consistent with the previously described TGF-β production, transcripts for genes encoding MMP2, MMP9, and MMP13 were expressed at higher levels in IECs from Clostridium -colonized mice compared with IECs from GF mice and Lactobacillus -colonized mice.
[0154] Furthermore, IDO was only expressed in Clostridium-colonized mice.
[0155] Thus, it appears that Clostridia activate IECs, which in turn lead to the production of TGF-β and other Treg cell-inducing molecules in the large intestine.
[0156] Example 11 We next investigated whether the accumulation of Treg cells induced by Clostridium colonization depends on signaling via pathogen-associated molecular pattern recognition receptors. Myd88 - / - ( Myd88 (deficient in the signaling adaptor for Toll-like receptors), Rip2 - / - (deficient in Rip2 (NOD receptor adaptor)), and Card9 - / - We investigated the number of Treg cells in the lamina propria of the colonic mucosa of SPF mice that lacked Card9 (a signaling factor essential for Dectin-1 signaling). Myd88 - / - We colonized GF mice with Clostridium bacteria and examined the change in Treg cell count. The results showed that the number of Treg cells in various SPF mice lacking factors related to pathogen-associated molecular pattern recognition receptors was unchanged compared to wild-type littermates. We also found that colonization of Myd88-deficient GF mice with Clostridium bacteria induced the accumulation of Treg cells in the lamina propria of the colonic mucosa. Therefore, it was suggested that the mechanism of induction of Treg cell accumulation in the lamina propria of the colonic mucosa depends on the specific commensal bacterial species, rather than on the activation of the major pathogen-associated molecular pattern recognition pathway, which is induced by most bacteria.
[0157] Example 12 Intestinal Foxp3 + Treg cells are known to exert some immunosuppressive functions through the production of IL-10 (see NPL9). + Foxp3 + It is known that animals in which IL-10 has been specifically removed from cells develop inflammatory bowel disease (see NPL18). Therefore, we first investigated the expression of IL-10 in lymphocytes of various tissues. Il10 venus Lymphocytes were isolated from various mouse tissues and the expression of CD4 and Venus was analyzed by flow cytometry.
[0158] Il10 venus Lymphocytes from the colonic lamina propria were isolated from mice, and T cell receptor β chain (TCRβ) expression on the cell surface was detected by FACS.
[0159] Il10 venus Lymphocytes were isolated from the colonic lamina propria of mice. They were stimulated with PMA (50 ng / ml) and ionomycin (1 μg / ml) for 4 h in the presence of Golgistop (BD Bioscience). After stimulation, intracellular cytokines were stained using anti-IL-17 PE antibody, anti-IL-4 APC antibody (11B11), and anti-IFN-g FITC antibody (BD Bioscience) according to the instructions of the cytofix / cytoperm kit (BD Bioscience).
[0160] In addition, Foxp3 eGFP Foxp3 from the spleen (Spl) of reporter mice + CD4 + Cells and Foxp3 - CD4 + Isolating cells Il10 venus Venus from the lamina propria of the large intestine and small intestine (SI) of mice +Cells were isolated. Each of the obtained cells was analyzed for the expression of a given gene. Gene expression was analyzed by real-time RT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) and ABI 7300 Real-Time PCR System (Applied Biosystems). Here, the value of each cell was normalized by the amount of GAPDH.
[0161] The result is Venus + The results show that Venus cells (IL-10-producing cells) were hardly detected in the cervical lymph nodes (peripheral lymph nodes), thymus, peripheral blood, lungs, and liver of mice maintained under SPF conditions. + Venus cells were detected in small amounts in the spleen, Peyer's patches, and mesenteric lymph nodes of the same mice. In contrast, the Venus cells were detected in the lamina propria lymphocytes of the small and large intestines. + Many Venus cells were observed in the intestine. + Most of the cells were CD4 positive and T cell receptor β chain (TCRβ) positive. + CD4 + The T cells did not show either Th2 (IL-4 producing) or Th17 (IL-17 producing) phenotypes, but were found to express Foxp3 and other Treg cell-associated factors, such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and glucocorticoid-inducible TNFR-related protein (GITR). + The expression level of CTLA-4 in cells was significantly increased by Foxp3 eGFP GFP in spleens isolated from reporter mice + This was found to be higher than the levels in Treg cells.
[0162] Example 13 Venus+ cells were divided into at least two subsets based on intracellular Foxp3 expression: Venus + Foxp3 + Double positive (DP) Treg cells and Venus + Foxp3 -The latter subset of cells corresponds to type 1 regulatory T cells (Tr1) (see NPLs 8 and 9). + The expression of Foxp3 was examined in IL-10 producing cells. Il10 venus Expression of CD4, Foxp3, and Venus in the lamina propria of the mouse large and small intestine was analyzed by FACS. + The cell count was determined by SPF. Il10 venus Mouse and GF Il10 venus was compared between mice.
[0163] Also, SPF Il10 venus The expression of intracellular Venus and Foxp3 in CD4 cells from various mouse tissues was analyzed by flow cytometry.
[0164] To investigate whether the presence of commensal bacteria has any effect on IL-10 expression in regulatory cells in the gastrointestinal tract, we performed a study in which we Il10 venus The resulting GF Il10 venus Mice were colonized with the indicated bacterial species. Three weeks after bacterial colonization, CD4+ cells expressing Foxp3 and / or Venus were detected in the large and small intestine. + Cell group (V + F - , Venus + Foxp3 - cell;V + F + , Venus + Foxp3 + cell;V - F + , Venus - Foxp3 + Cells) were analyzed by flow cytometry.
[0165] To determine whether the presence of commensal bacteria has any effect on IL-10 expression in regulatory cells in the gut, antibiotics were administered to 5 or 6 mice per group. Il10 venus Mice were given the following antibiotics in combination with water for 10 weeks: Ampicillin (A; 500 mg / L, Sigma) Vancomycin (V; 500mg / L, NACALAI TESQUE, INC.) Metronidazole (M; 1g / L, NACALAI TESQUE, INC.) Neomycin (N; 1g / L, NACALAI TESQUE, INC.)
[0166] Lymphocytes from the colonic lamina propria, small intestinal (SI) lamina propria, mesenteric lymph nodes (MLN), and Peyer's patches (PP) were then stained with antibodies for CD4 and Foxp3 and analyzed by FACS. Results were obtained from more than two independent experiments giving nearly identical results.
[0167] The results showed that Venus + Foxp3 - There are many Tr1-like cells in the large intestine, and Venus + Foxp3 + In contrast, there were sufficient numbers of Foxp3 Treg cells in other tissues. + Cells were observed, but most of the cells did not express Venus.
[0168] Also, Venus in the large intestine + Foxp3 - , Venus + Foxp3 + , and Venus - Foxp3 + We found that all regulatory T cell fractions in SPF mice were significantly decreased under GF conditions. II10 Venus Similarly, Venus can be used with mice. +A decrease in cells was observed.
[0169] Clostridium colonization is associated with the Venus + Foxp3 - , Venus + Foxp3 + , and Venus - Foxp3 + All regulatory T cell subpopulations were strongly induced, and the degree of induction was similar to that in SPF mice. Furthermore, colonization with three strains of Lactobacillus spp. and SFB significantly increased the number of Venus spp. + and / or Foxp3 + The effect on cell numbers was negligible. Furthermore, the colonization of 16 strains of Bacteroides was also significantly improved by Venus. + The cells were induced, but the effect of the fixation was not + Foxp3 - The effect of IL-10 on the number of IL-10-producing cells in the small intestinal lamina propria was specific to Tr1-like cells. In contrast, none of the tested bacterial species was found to have any significant effect on the number of IL-10-producing cells in the small intestinal lamina propria (see FIG. 26).
[0170] Therefore, it is believed that Clostridium bacteria colonizing the large intestine or physiologically active substances derived from said bacteria inhibit IL-10. + It was revealed that it induces accumulation of regulatory T cells in the colonic lamina propria or induces IL-10 expression in T cells. + The cell numbers were not significantly affected by the absence or reduction of commensal bacteria, and IL-10+ regulatory cells (Tr1-like cells) were found to accumulate in the lamina propria of the small intestine mucosa regardless of the presence of commensal bacteria.
[0171] Example 14 Venus induced by Clostridium bacteria + The cells were isolated from the Venus colon of SPF mice. + We investigated whether CD4 cells isolated from the spleen have the same immunosuppressive function as CD4 cells. + CD25 -Cells (effector T cells, Teff cells) were cultured in a flat-bottom 96-well plate at 2 × 10 4 2 × 10 cells / well were seeded and treated with 30 Gy radiation. 4 Spleen CD11c + The mice were cultured for 3 days with 0.5 μg / ml of anti-CD3 antibody and a large number of Treg cells. 3 H]-thymidine (1 μCi / well) was added to CD4 + CD25 - The Treg cells used in Example 14 were cultured using the Foxp3 eGFP CD4 isolated from the spleens of reporter mice + GFP + T cells or GF colonized with Clostridium bacteria Il10 venus Mouse or SPF Il10 venus CD4 in the lamina propria of mouse colon + Venus + T cells. 3 Cell proliferation was measured by incorporation of [H]-thymidine and expressed as counts per minute (cpm).
[0172] The results showed that the clostridium-infected mice with Venus + CD4 + Cells expressing CD25 in vitro - CD4 + This shows that the proliferation of activated T cells was suppressed. This suppressive activity was due to the expression of Foxp3 eGFP GFP isolated from reporter mice + Although slightly inferior to cells, SPF Il10 venus Venus isolated from mouse + Thus, Clostridium bacteria play an important role in maintaining immune homeostasis in the large intestine by inducing IL-10-expressing T cells with sufficient immunosuppressive activity.
[0173] Example 15 We next investigated the effect of heavy Clostridium colonization on local immune responses and the resulting expansion of Treg cells.
[0174] <Dextran Sodium Sulfate (DSS)-Induced Colitis Model> First, we created a DSS-induced colitis model as described above, and examined the effects of Clostridium inoculation and Treg cell proliferation on the model mice. Specifically, after treating control mice and Clostridium inoculated mice with 2% DSS, we observed and measured weight loss, stool consistency, and bleeding for 6 days and evaluated them numerically. In addition, on the 6th day, the colons were collected, dissected, and histologically analyzed by HE staining.
[0175] The results show that symptoms of colitis, such as weight loss and rectal bleeding, were significantly suppressed in mice with high amounts of Clostridium (hereafter also referred to as "Clostridium-rich mice") compared with control mice (C57BL / 6 mice housed in a conventional environment for 6 weeks and not inoculated with fecal suspension). All typical features of colonic inflammation, such as shortening of the colon, edema, and bleeding, were significantly more pronounced in control mice than in Clostridium-rich mice. Furthermore, histological features, such as mucosal erosion, edema, cellular infiltration, and crypt loss, were less severe in DSS-treated Clostridium-rich mice than in control mice.
[0176] <Oxazolone-induced colitis model> Next, we created an oxazolone-induced colitis model as described above, and examined the effects of Clostridium inoculation and Treg cell proliferation on the model mice. Specifically, control mice and Clostridium inoculated mice were sensitized with oxazolone, and then the inside of the rectum was treated with a 1% oxazolone / 50% ethanol solution. Body weight loss was then observed and measured. Furthermore, the colons were dissected and histologically analyzed by HE staining.
[0177] Results show that control mice developed colitis accompanied by persistent weight loss, whereas Clostridium-enriched mice experienced reduced weight loss, and the colons of Clostridium-enriched mice showed reduced areas of histological disease, including mucosal erosions, edema, cellular infiltration, and hemorrhage.
[0178] Example 16 Next, we examined the effect of colonization with a large amount of Clostridium and the resulting proliferation of Treg cells on the systemic immune response (systemic IgE production). Specifically, as described above, control mice and Clostridium-inoculated mice were immunized with ovalbumin (OVA) adsorbed to alum twice at an interval of 2 weeks. Serum was then collected from these mice, and the levels of OVA-specific IgE were examined by ELISA. In addition, splenocytes were collected from each group of mice, and the production of IL-4 and IL-10 following in vitro OVA restimulation was examined.
[0179] The results show that IgE levels were significantly lower in Clostridium-enriched mice than in control mice. Furthermore, splenocytes from Clostridium-enriched mice sensitized with OVA and alum produced reduced IL-4 and increased IL-10 upon OVA restimulation compared to control mice.
[0180] Therefore, taken together with the results shown in Example 15, the induction of Treg cells in the large intestine by Clostridium plays an important role in local and systemic immune responses.
[0181] Example 17 Next, GF Balb / c mice were colonized with three Clostridium strains belonging to cluster IV (strains 22, 23, and 32 listed in Figure 49). After 3 weeks, colonic Foxp3 + Treg cells were analyzed by FACS. The results showed that the induction pattern of Treg cells in gnotobiotic mice colonized with 3 Clostridium strains was intermediate between that in GF mice and mice inoculated with all 46 strains.
[0182] Example 18 Next, we investigated whether the spore-forming (e.g., chloroform-resistant) fraction of fecal samples collected from humans had the effect of inducing the proliferation or accumulation of regulatory T cells, similar to the spore-forming fraction of fecal samples collected from mice.
[0183] Human feces from a healthy subject (Japanese, male, 29 years old) were suspended in phosphate-buffered saline (PBS), mixed with chloroform (final concentration: 3%), and then incubated in a shaking water bath for 60 min. After evaporating the chloroform by bubbling N2 gas, aliquots containing the chloroform-resistant (e.g., spore-forming) fraction of human intestinal bacteria were orally inoculated into germ-free (GF) mice (IQI, 8 weeks old). Treated mice were kept in vinyl isolators for 3 weeks. The large intestines were collected, incised longitudinally, washed to remove fecal contents, and shaken in Hank's balanced salt solution (HBSS) containing 5 mM EDTA for 20 min at 37 °C. After removing epithelial cells and adipose tissue, the colon was dissected and incubated with RPMI1640 containing 4% fetal bovine serum, 1 mg / ml collagenase D, 0.5 mg / ml dispase and 40 μg / ml DNaseI (all from Roche Diagnostics) for 1 h at 37°C in a oscillating water bath. The digested tissue was washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (GE Healthcare) and layered on 2.5 ml of 80% Percoll in a 15 ml Falcon tube. Percoll gradient separation was performed by centrifugation at 780 g for 20 min at 25°C. The cells at the interface were collected and suspended in staining buffer containing PBS, 2% FBS, 2 mM EDTA and 0.09% NaN3, and cell surface CD4 was stained with phycoerythrin-conjugated anti-CD4 antibody (RM4-5, BD Biosciences). Intracellular staining of Foxp3 was performed using Alexa647-labeled anti-Foxp3 antibody (FJK-16s, eBioscience) and Foxp3 Staining Buffer Set (eBioscience). The percentage of Foxp3-positive cells in the CD4-positive lymphocyte population was analyzed by flow cytometry.
[0184] The results show that colonization of GF mice with spore-forming (e.g., chloroform-resistant) fractions of human intestinal bacteria induced the accumulation of Fox3+ regulatory (Treg) cells in the lamina propria of the mouse colonic mucosa.
[0185] Next, we investigated what bacterial species grew when chloroform-treated human feces was forcefully administered orally.
[0186] Specifically, bacterial genomic DNA was isolated from human feces of healthy subjects (human feces) or fecal pellets of GF mice administered chloroform-treated human feces (GF+Chloro.) using the QIAamp DNA Stool Mini Kit (QIAGEN). Quantitative PCR analysis was performed using a LightCycler480 (Roche). Relative amounts were calculated by the delta Ct method and normalized to the total bacterial amount, dilution, and sample weight. The following primer sets were used: Total bacteria 5'-GGTGAATACGTTCCCGG-3' (SEQ ID NO: 62) and 5'-TACGGCTACCTTGTTACGACTT-3' (SEQ ID NO: 63) Clostridium cluster XIVa (Clostridium coccoides subgroup) 5'-AAATGACGGTACCTGACTAA-3' (SEQ ID NO:64) and 5'-CTTTGAGTTTCATTCTTGCGAA-3' (SEQ ID NO: 65) Clostridium cluster IV (Clostridium leptum) 5'-GCACAAGCAGTGGAGT-3' (SEQ ID NO: 66) and 5'-CTTCCTCCGTTTTGTCAA-3' (SEQ ID NO: 69) Bacteroides 5'-GAGAGGAAGGTCCCCCAC-3' (SEQ ID NO: 67) and 5'-CGCTACTTGGCTGGTTCAG-3' (sequence number: 68).
[0187] The results show that oral gavage of chloroform-treated human feces showed a high abundance of spore-forming bacteria, such as Clostridium cluster XIVa and IV, and a significant reduction in non-spore-forming bacteria, such as Bacteroides, compared to human feces before chloroform treatment.
[0188] Example 19 Human feces (2 g) from a healthy subject (Japanese, male, 29 years old) was suspended in 20 ml of phosphate-buffered saline (PBS), mixed with or without chloroform (final concentration 3%), and incubated in a shaking water bath for 60 min. The chloroform was then evaporated by bubbling N2 gas for 30 min. The suspensions of untreated human feces (named "huUT") and chloroform-treated human feces (named "huChloro") were orally inoculated (250 μl / mouse) into germ-free (GF) mice (IQI, 8 weeks old). The huUT suspension was inoculated into four GF mice numbered #A1 to #A4, and the huChloro suspension was inoculated into four GF mice numbered #B1 to #B4. The GF mice inoculated with such fecal suspensions are hereafter also referred to as "ex-GF mice". To avoid further microbial contamination of the mice, each group of ex-GF mice was housed separately in vinyl isolators. After 3 weeks, lymphocytes from the small intestinal and colonic lamina propria were collected separately from each mouse and examined for surface CD4 and intracellular Foxp3, Helios, IL-17, and IFN-γ expression by flow cytometry. For intracellular IL-17 and IFN-γ staining, isolated lymphocytes were stimulated in vitro with PMA and ionomycin for 4 h. Foxp3 is a transcription factor essential for Treg cell differentiation and function. Helios is a member of the Ikaros transcription factor family, and Helios-Foxp3 + It has been suggested that Treg cells are peripherally induced Treg cells [so-called induced Treg (iTreg) cells]. As shown in Figures 1A-1D, CD4 + Foxp3 in T cells +The proportion of Treg cells was increased in both groups of ex-GF mice compared with GF mice. Foxp3 + A significant increase in the proportion of Helios- cells among Treg cells was also observed. + In addition to Treg cells, exGF+huUT mice also expressed IL-17-expressing CD4 + A significant accumulation of Th17 cells was observed in the exGF+huChloro mice, whereas only a slight accumulation was observed in the exGF+huChloro mice (Fig. 1E and 1F). + IFN-γ in cells + No change in the proportion of cells was observed (Figures 1E and 1G).
[0189] Example 20 To examine whether killed bacteria also affect the induction of Treg cells, a suspension of chloroform-treated human feces was autoclaved (121°C for 20 min) and orally inoculated into GF mice (once a week for 4 weeks). After 4 weeks, the mice were sacrificed, and lymphocytes in the colonic lamina propria of each mouse were examined for expression of CD4, Foxp3, and Helios by flow cytometry. As shown in Figure 2, inoculation of killed bacteria significantly increased the expression of Foxp3. + Helios-Foxp3 also affects cell count + Although these results do not exclude the possibility that the amount of killed bacteria inoculated was insufficient, they do suggest that live bacteria are necessary for the induction of Treg cells.
[0190] Example 21 To confirm the induction of Treg cells by chloroform-resistant bacteria, feces were freshly collected from the same subject on a different day, treated with chloroform, and inoculated into IQI GF mice (seven mice numbered #C1 to #C7). After 3 to 4 weeks, mice #C1 to #C5 were sacrificed, and lymphocytes from the small intestine and the colonic lamina propria were collected separately from each mouse and examined for CD4 and Foxp3 expression by flow cytometry. Consistent with the results of Example 19, colonization with chloroform-treated human feces increased the expression of Foxp3 in the colonic and small intestinal lamina propria. + CD4 + The accumulation of Treg cells was significantly induced (Figure 3). These results further support that chloroform-resistant spore-forming bacteria can induce the differentiation, proliferation and / or recruitment of Treg cells in the intestinal lamina propria.
[0191] Example 22 To test whether induction of Treg cells by chloroform-resistant spore-forming fractions of human intestinal bacteria is horizontally transferable, IQI GF mice (six mice numbered #D1 to #D6) were housed with mice #C6 and #C7 in the same cage in a vinyl isolator for 4 weeks. Lamina propria lymphocytes from the large and small intestines were isolated and examined for CD4 and Foxp3. + Foxp3 in cells + A significant increase in the proportion of Treg cells was observed (Figure 4). Therefore, Treg cell induction by human gut bacteria is horizontally transferable. These results suggest that the abundant rather than the few constituent bacteria of the gut microbiota plays a role in the induction of Treg cells.
[0192] Example 23 Frozen stocks of cecal contents from mouse #C4 were thawed, suspended in 10 volumes (w / v) of PBS, and passed through a 70 μm cell strainer. The suspensions were then treated with 3% chloroform, diluted 2000-fold or 20,000-fold in PBS, and orally inoculated into GF IQI mice (2.5 × 10 bacterial cells, respectively). 5 pcs or 2.5×10 4The 2000-fold diluted sample was orally inoculated into four individuals (named exGF+2000 and numbered #E1 to #E4), and the 20,000-fold diluted sample was inoculated into eight individuals (named exGF+20000 and numbered #F1 to #F8). After three weeks, lymphocytes from the intestinal mucosa lamina propria were isolated and examined for CD4, Foxp3, and Helios. Both the 2000-fold diluted sample and the 20,000-fold diluted sample showed similar levels of Foxp3 in the intestinal mucosa lamina propria. + CD4 + The amount of bacteria orally inoculated was 2.5 × 10 4 It can be minimized to less than a bacterial cell.
[0193] Example 24 Frozen stocks of cecal contents from mice #F3, #F7, or #F8 were suspended in 10 volumes (w / v) of PBS, passed through a 70 μm cell strainer, and treated with 3% chloroform. The fecal suspension from mouse #F3 was then orally inoculated into five GF mice (numbered #G1 to #G5), the fecal suspension from mouse #F7 into four GF mice (numbered #H1 to #H4), and the fecal suspension from mouse #F8 into four GF mice (numbered #I1 to #I4). Four weeks later, lymphocytes from the lamina propria of the large and small intestine mucosa were isolated and the expression of CD4, Foxp3, and Helios was examined by flow cytometry. In all mice #F, #G, and #H, CD4 in the lamina propria of the intestinal mucosa was significantly higher than that in the control mice. + Foxp3 in cells +The percentage of Treg cells was significantly increased compared to untreated GF mice (Figure 6). Therefore, Treg cell induction by human gut bacteria colonization in exGF+20000 mice is also transferable. Furthermore, as shown by the subsequent meta 16S rDNA sequencing data (Figure 8), these mice were colonized with 20 known species of bacteria (C. aminophilum, H. saccgarovorans, E. fissicatena, H. filiformis, C. clostridioforme, C. indolis, C. bolteae, Bacteroides sp. MANG, L. typhimurium DJF_VP30, Ruminococcus sp. Bacteria with 16S rDNA sequence similarity to Clostridium sp. ID8, C. lavalense, C. symbiosum, E. contortum, C. saccharogumia, C. ramosum, F. plautii, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf. Clostridium sp. MLG055 were commonly found.
[0194] Example 25 Frozen stocks of cecal contents from #F8 mice were serially diluted in 0.85% NaCl under aerobic conditions and plated on BL agar. After 2 or 4 days of incubation at 37°C, 50 single colonies were observed. Of the 50 colonies, 29 colonies were picked, cultured in ABCM broth at 37°C for an additional 2 or 4 days, and stored at -80°C in EG stock medium (10% DMSO). Genomic DNA from each colony was isolated, and the 16S rRNA coding gene sequence was analyzed. The 16S rRNA sequences of each colony revealed that the 29 colonies examined were represented by three strains, each with 100% similarity to Clostridium ramosum, 99.75% similarity to Clostridium saccharogumia, 100% similarity to Flavonifractor plautii, 99.17% similarity to Clostridium hathewayi, 99.23% similarity to Clostridium scindens, or 99.66% similarity to Clostridium sp. 2335. Of the original 50 colonies, 29 were selected in which only Clostridium saccharogumia, Clostridium ramosum, and Flavonifractor plautii were present (25, 3, and 1 colonies, respectively). These three isolates were propagated, mixed, and inoculated into GF IQI mice (four individuals numbered #J1-J4). After 3-4 weeks, lymphocytes from the colonic lamina propria were harvested and examined by flow cytometry for expression of CD4, Foxp3, and Helios. Foxp3 +No or only minimal Treg cells were induced by colonization of the large intestine with the three bacterial strains (Figure 7). These results suggest that the combination of Clostridium saccharogumia and Clostridium ramosum (both of which are in cluster XVIII) is not sufficient to induce Treg cells in the mouse large intestine. The effect of Flavonifractor plautii was not clear because it represented only one of the 29 selected colonies.
[0195] Example 26 Similar to the method carried out in Example 19, frozen glycerol stocks of cecal contents from #G2 mice were suspended in PBS, plated on BL agar plates, and incubated for 48 hours. Unlike in Example 19, all bacteria on the plates were scraped off with a plate scraper, collected, suspended in TS broth, and inoculated into GF IQI mice (four mice numbered #K1 to #K4). It should be noted that the bacterial suspension used in this experiment contained bacteria that did not grow on the plates but survived. After 4 weeks, lymphocytes from the lamina propria of the mucosa were isolated from the large and small intestines of K1 to K4 mice and examined for expression of CD4, Foxp3, and Helios. In all four mice, CD4 in the intestinal lamina propria was detected. + Foxp3 in cells + The percentage of cells expressing Foxp3 + The proportion of Helios- cells in Treg cells (Fig. 9A, 9C) was significantly increased compared to untreated GF mice. Considering that Treg cells were not induced in mice inoculated with the six strains of bacteria that grew on BL agar plates, it is possible that bacteria that did not grow on the plates but survived are involved in the induction of Treg cells.
[0196] Example 27 Bacterial DNA was extracted from the cecal contents of mice #A1, #C4, #F8, #G2, #H3, #I3, #J3 and #K3. Variable regions 1-2 (V1-2) of the gene encoding bacterial 16S rRNA were amplified by PCR and used as templates for meta-sequencing. The obtained sequences (3400 reads for each sample) were classified into operational taxonomic units (OTUs) based on sequence similarity (>97% identity). Representative sequences of each OTU were compared with sequences in nucleic acid databases using BLAST to determine the closest relatives of known species. The number of reads detected for each OTU and the closest relatives are shown in Table 1. The relative abundance of OTUs with the same closest relatives for each cecal sample is shown in Figure 8. 153 OTUs (93 were the closest relatives) were identified in mouse #A1, half of which were closely related to Bacteroides species. In contrast, 113 OTUs were identified in mouse #C4, most of which were closely related to species belonging to the family Clostridiaceae, whereas 97–68 OTUs were identified in mouse #F8, #G2, #H3, #I3, #J3, and #K3.In these mice, accumulation of Treg cells was observed in the intestine, with the majority of bacteria identified as C. aminophilum, H. saccgarovorans, E. fissicatena, H. filiformis, C. clostridioforme, C. indolis, C. bolteae, Bacteroides sp. MANG, L. typhimurium DJF_VP30, and Ruminococcus sp. The isolates consisted of bacteria with 16S rDNA sequence similarity to cf. Clostridium sp. ID8, C. lavalense, C. symbiosum, E. contortum, C. saccharogumia, C. ramosum, F. plautii, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf. Clostridium sp. MLG055.
[0197] In mouse #J3, no Treg accumulation was observed, and three OTUs were detected, each of which had 16S rDNA sequence similarity to C. saccharogumia, C. ramosum, or F. plautii. These results suggest that the combination of these three species is insufficient to induce Treg cell accumulation in the intestine.
[0198] Example 28 Bacterial strains were isolated from the cecal contents of mice #F8, #G2, #I1, and #K3 using BL agar or EG agar plates. 144 colonies were selected from the EG agar plates and 116 colonies from the BL agar plates. BLAST searches of the 16S rRNA coding sequences of these clones revealed that they belonged to 17 species, including C. indolis, C. bolteae, Bacteroides sp. MANG, L. typhimurium DJF_VP30, A. colihominis, Ruminococcus sp. ID8, C. lavalense, C. symbiosum, E. contortum, C. saccharogumia, C. ramosum, F. plautii, C. hathewayi, C. scindens, and Clostridium sp. It was revealed that the bacteria had 93-100% homology with Clostridium sp. 2335, Clostridium sp. 14616, and cf Clostridium sp. MLG055 (Table 2). All of the bacteria listed here belong to Clostridium clusters IV, XIVa, or XVIII (two species in cluster IV, 12 species in cluster XIVa, one species in cluster XVI, and two species in cluster XVIII).
[0199] Example 29 Additional colonies were selected and isolated from the colonies selected in Example 28, and these strains were cultured using EG and BL media. BLAST searches of the 16S rRNA coding sequences of these clones revealed that these strains belonged to a total of 31 species (including the species listed in Example 28), including Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum WM2, Bacteroides sp. MANG, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Bacterium saccharolyticum WM1, Bacterium saccharolyticum WM2, Bacterium saccharolyticum WM1 ...3, Bacterium saccharolyticum WM4, Bacterium saccharolyticum WM5, Bacterium saccharolyticum WM6, Bacterium saccharolyticum WM7, Bacterium saccharolyticum WM8, Bacterium saccharolyticum WM9, Bacterium saccharolyticum WM10, Bacterium saccharolyticum WM11, Bacterium saccharolyticum WM12, Bacterium saccharolyticum WM13, Bacterium saccharolyticum WM14, Bacterium saccharolyticum saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp.) 316002 / 08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM14662 (Table 3). Stocks of bacterial strains were kept in 10% glycerol plus the medium used to grow the cultures, and tubes were stored in a -80°C freezer.
[0200] Example 30 To examine whether the strains in Example 29 have the ability to induce Tregs in GF mice, the 31 strains in Table 3 were mixed in an equal volume of medium using TS medium and inoculated into GF mice. Detailed analysis of the 16S rRNA sequences revealed that 8 of the 31 strains overlapped with other strains (see Table 3, indicated by an asterisk), resulting in 23 different bacterial strains. As shown in Figure 10, oral administration of a mixture of 23 strains (23mix) to GF mice induced extremely strong levels of Tregs (35-40% in the colonic lamina propria and over 10% in the small intestine; Figure 10). Most of these Tregs observed in colonization with 23mix were Helios - It was.
[0201] Example 31 To examine whether the chloroform-resistant fraction of human intestinal bacteria, which is present in large numbers in the intestinal microbiota, is responsible for the induction of Treg cells, adult GF mice were inoculated with diluted cecal samples from mice inoculated with the chloroform-resistant fraction of human intestinal bacteria (+huChlo mice) as described in Example 19. As shown in FIG. 11, +2×10 4 Mouse and 2 × 10 5 Dilute the huChlo mouse cecal sample (2 x 10) to generate mice. 4 and 2 × 10 5 Even when the antibody was diluted to 100 mM, Tregs were induced in these adult GF mice.
[0202] Example 32 To examine whether the mixture of 23 strains in Example 30 has the ability to induce Tregs in adult GF IQI mice more effectively than Faecalibacterium prausnitzii, a well-known human Clostridium strain characterized by enhancing the function of regulatory cells, the 23 strains in Table 4 were mixed in equal amounts with culture medium to prepare a cocktail, which was then administered to adult IQI GF mice. For comparison, Faecalibacterium prausnitzii was administered to another group of IQI GF mice. As shown in FIG. 12, oral administration of the mixture of 23 strains (23-mix) to adult IQI GF mice induced higher levels of Tregs than Faecalibacterium prausnitzii. Faecalibacterium prausnitzii (+Faecali.) showed negligible levels of Treg induction.
[0203] Example 33 +2×10 as described in Example 31 4 To examine whether the mouse microbiota was stable, adult GF mice were serially orally inoculated with +2 × 10 4 -re mice (secondary inoculation) and +2 × 10 4 -re-re mice (tertiary inoculation) were generated. As shown in FIG. 4 -re Mouse, +2×10 4 In both -re-re mice, significant induction of Tregs was observed. To further eliminate components of the microbiota that are not necessary for inducing Treg cells, +2×10 4 The cecal contents of the mice were then resuspended in 2 × 10 4 2x10 diluted and injected into another group of adult GF mice (+(2x10 4 ) 2 As shown in FIG. 13, +(2×10 4 ) 2In mice, a significant accumulation of Treg cells was observed in the large intestine.
[0204] Example 34 +huUT (+hu), +huChlo, +2×10 4 , +2×10 4 -re and +(2x10 4 ) 2 To assess the composition of the gut microbiota in +hu mice, bacterial DNA was extracted from the cecal contents of these adult mice. Variable regions (V1–V2) of bacterial 16S ribosomal DNA (rDNA) were amplified and meta-sequencing was performed using a 454 sequencer. The resulting sequences (3400 reads for each sample) were grouped into operational taxonomic units (OTUs) based on sequence similarity (>96% identity). Representative sequences from each OTU were compared with sequences deposited in public 16S and genome databases using BLAST to determine the closest related species. As shown in Figure 14, in +hu mice, OTUs belonging to the phylum Bacteroidetes accounted for approximately 50% of the cecal microbial community. In contrast, most OTUs in +huChlo mice were closely related to species belonging to Clostridium. +2×10 4 , +2×10 4 -re and +(2x10 4 ) 2 In mice, the majority of the bacteria consisted of approximately 20 species of Clostridia and bacteria with 16S rDNA sequence similarity belonging to clusters XIVa (also called C. leptum group), IV, XVI, and XVIII listed in Figure 14.
[0205] Example 35 A 16S rDNA meta-analysis was performed on the cecal contents of mice inoculated with the 23 strains isolated in Example 30 (+23-mix mice), confirming the presence of 17 of the 23 strains listed in Figure 14 and Table 4. To determine whether the 17 strains could induce Treg cells, a mixture of these 17 strains was inoculated into adult GF mice (+17-mix mice). Each bacterial strain was cultured in 2 mL of EG liquid medium and grown to confluence, and then these starter cultures were mixed in a 50 mL tube (2 mL x 17 strains = 34 mL). The bacteria were spun down to a pellet and resuspended in 10 mL of PBS. Approximately 1 x 10 6 ~1×10 7 A 200 μL aliquot containing 17 strains was used to inoculate adult GF mice. As shown in Figure 15, oral administration of the 17 strain mixture to IQI, BALB, and B6 adult mice was able to induce Tregs in these three mouse models.
[0206] Example 36 To examine whether each of the 17 strains identified in Example 35 can induce Tregs individually, adult GF mice were monocultured with each of the 17 strains. As shown in Figure 16, low to medium levels of Tregs were observed in adult GF mice monocultured with a single strain. Importantly, no single strain induced Tregs to the same extent as the mixture of the 17 strains.
[0207] Example 37 To examine whether a subset of the 17 strains described in Example 35 can induce Tregs, combinations of 3 to 5 randomly selected strains, 3-mix, 5mixA, 5-mixB, and 5-mixC, were prepared and used to inoculate adult GF mice, as shown in Table 4. As shown in Figure 17, only the 5-mix induced a significant increase in the frequency of Treg cells, and the degree of increase was moderate compared to that observed in +17-mix mice.
[0208] Example 38 To examine the beneficial effects of administering the 17-strain mixture (17-mix) described in Example 35, adult SPF mice were orally inoculated with either 17-mix or control medium, and Foxp3 + The induction of Treg cells was evaluated. As shown in FIG. 18, after 3 weeks of treatment, the induction of Foxp3 + A significant increase in the frequency of Treg (CD4) cells was observed.
[0209] Example 39 To investigate the benefit of 17-mix administration in an animal model of allergic diarrhea, adult SPF mice were orally inoculated with 17-mix or control medium and treated with ovalbumin (OVA), an inducer of allergic diarrhea, during this period. As shown in Figure 19, the frequency and severity of diarrhea (diarrhea score) were significantly reduced in mice administered 17-mix compared to control mice.
[0210] Example 40 To investigate the benefit of 17-mix administration in an animal model of colitis, adult SPF mice were orally inoculated with either 17-mix or control medium and treated with trinitrobenzene sulfonic acid (TNBS), a substance commonly used to experimentally induce colitis, during this period. As shown in Figure 20, SPF 17-mix mice showed lower mortality than control mice upon exposure to TNBS.
[0211] Example 41 To evaluate the usefulness of the strains shown in the 17-mix as diagnostic and monitoring tools for ulcerative colitis, the relative abundance of the 17 strains in healthy and ulcerative colitis (UC) subjects was examined using the 17 strains and the draft genome sequence of the human fecal microbiome genome produced and published by the European MetaHIT project. As shown in Figure 21, the 17 strains were found to be reduced in UC subjects (N=20) compared to healthy subjects (N=15).
[0212] Sequence number:OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367 are sequence numbers 19 to 44, respectively. [Industrial Applicability]
[0213] As described above, the compositions and methods described herein make it possible to provide a well-characterized and excellent composition for inducing the proliferation or accumulation of regulatory T cells (Treg cells) by utilizing a specific human-derived bacterium belonging to the genus Clostridium or a physiologically active substance derived from the bacterium. Since the bacterial composition has an immunosuppressive effect, it can be used, for example, to prevent or treat autoimmune diseases or allergic diseases, and to suppress immune rejection in organ transplants. Furthermore, healthy individuals can easily ingest the bacterial composition on a daily basis in the form of food or drink (e.g., health food) to improve immune function.
[0214] [Table 1A-1] [Table 1A-2]
[0215] [Table 1B-1] [Table 1B-2]
[0216] [Table 2]
[0217]
Table 3-1
Table 3-2
[0218]
Table 4-1
Table 4-2
Table 4-3
Table 4-4
[0219]
Table 5-1
[0220]
Table 5-2
[0221]
Table 5-3
[0222]
Table 5-4
[0223]
Table 5-5
[0224]
Table 5-6
[0225]
Table 5-7
[0226]
Table 5-8
[0227]
Table 5-9
[0228]
Table 5-10
[0229]
Table 5-11
[0230]
Table 5-12
[0231]
Table 5-13
[0232]
Table 5-14
[0233]
Table 5-15
[0234]
Table 5-16
[0235]
Table 5-17
[0236]
Table 5-18
[0237]
Table 5-19
[0238]
Table 5-20
[0239]
Table 5-21
[0240]
Table 5-22
[0241]
Table 5-23
[0242]
Table 5-24
[0243]
Table 5-25
[0244]
Table 5-26
[0245]
Table 5-27
[0246]
Table 5-28
Claims
1. A drug for inducing proliferation and / or accumulation of regulatory T cells, the drug comprising, as an active ingredient, the following: (a) a strain belonging to operational taxonomic unit (OTU) 136 and containing a 16S rDNA with at least 95% sequence identity to SEQ ID NO:19; (b) a strain belonging to OTU 46 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO:20; (c) a strain belonging to OTU 221 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO:21; (d) a strain belonging to OTU 9 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO:22; (e) a strain belonging to OTU 21 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO:24; (f) a strain belonging to OTU 166 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO:25; (g) a strain belonging to OTU 174 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO:27; (h) a strain belonging to OTU 337 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO: 30; (i) a strain belonging to OTU 314 and containing a 16S rDNA that has at least 95% sequence identity to SEQ ID NO: 31; (j) a strain belonging to OTU 195 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO: 32; (k) a strain belonging to OTU 306 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO: 33; (l) a strain belonging to OTU 87 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO: 34; (m) a strain belonging to OTU 281 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO: 39; (n) a strain belonging to OTU 288 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO: 40; (o) a strain belonging to OTU 334 and containing a 16S rDNA having at least 95% sequence identity to SEQ ID NO: 41; and (p) A strain belonging to OTU 359 and containing a 16S rDNA having at least 95% sequence identity with SEQ ID NO:
42. wherein the strain of the drug is present in one or more compositions.
2. The strain of (a) comprises a 16S rDNA sequence that has at least 96% sequence identity to SEQ ID NO:19; (b) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:20; (c) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:21; (d) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:22; (e) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:24; (f) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:25; (g) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:27; (h) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:30; (i) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:31; (j) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:32; (k) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:33; (l) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:34; (m) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO:39; (n) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO: 40; (o) the strain comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO: 41; and The strain of (p) comprises a 16S rDNA sequence having at least 96% sequence identity to SEQ ID NO: 42; The drug according to claim 1.
3. The drug according to claim 1 or 2, wherein the drug comprises at least 10 strains of (a) to (p).
4. The drug according to any one of claims 1 to 3, wherein the drug comprises a strain of (a) to (p).
5. Regulatory T cells are FOXP3 + The drug according to any one of claims 1 to 4, which is a regulatory T cell.
6. The drug according to any one of claims 1 to 5, wherein the regulatory T cells are IL-10-producing regulatory T cells.
7. The method according to any one of claims 1 to 6, wherein one or more of the strains is in spore form.
8. The method according to any one of claims 1 to 7, wherein the strain is freeze-dried.
9. The medicament according to any one of claims 1 to 8, wherein one or more compositions are formulated for oral or rectal administration.
10. The medicament of any one of claims 1 to 9, wherein one or more compositions are formulated for oral administration.
11. The medicament of any one of claims 1 to 10, wherein one or more compositions are formulated for delivery to the intestine.
12. The medicament of any one of claims 1 to 11, wherein one or more compositions are formulated for delivery to the large intestine.
13. The medicament of any one of claims 1 to 12, wherein each of the one or more compositions comprises a pH sensitive composition comprising one or more enteric polymers.
14. The method of any one of claims 1 to 13, wherein each of the one or more compositions comprises a hydrogel.
15. The medicament of claim 14 , wherein the hydrogel comprises a cellulosic polymer.
16. The medicament according to any one of claims 1 to 15, wherein each of the one or more compositions is in the form of a capsule.
17. The method according to any one of claims 1 to 16, wherein the strains are present in more than one composition, each composition comprising at least one of the strains.
18. The method according to any one of claims 1 to 16, wherein the strains are present in a single composition.
19. A medicament according to any one of claims 1 to 18 for use in a method for treating or preventing autoimmune, inflammatory, allergic and infectious diseases in a subject.
20. A medicament according to any one of claims 1 to 18 for use in a method for treating or preventing an autoimmune disease.
21. The method of claim 20, wherein the autoimmune disease is inflammatory bowel disease (IBD).
22. The method of claim 21 , wherein the IBD is Crohn's disease or ulcerative colitis.
23. The method of claim 21 or 22, wherein the IBD is ulcerative colitis.
24. A medicament according to any one of claims 1 to 18 for use in a method for treating or preventing an allergic disease.
25. The drug according to claim 24, wherein the allergic disease is food allergy.
26. A medicament according to any one of claims 1 to 18 for use in a method for treating or preventing an inflammatory disease.
27. The method of claim 26, wherein the inflammatory disease is graft-versus-host disease (GvHD).
28. A medicament according to any one of claims 1 to 18 for use in a method for treating an infectious disease or for preventing said disease.
29. The method of claim 28, wherein the infection is an infection caused by Clostridium difficile.
30. The method of claim 28, wherein the infection is a recurrent infection caused by Clostridium difficile.
31. The method according to any one of claims 1 to 18, wherein the administration of the one or more compositions is performed after treatment with one or more antibiotics.
